

Enantioenriched α -Vinyl 1,4-Benzodiazepines and 1,4-Benzoxazepines via Enantioselective Rhodium-Catalyzed Hydrofunctionalizations of Alkynes and Allenes

Álvaro Velasco-Rubio, Rodrigo Bernárdez, Jesús A. Varela, and Carlos Saá*



Cite This: *J. Org. Chem.* 2021, 86, 10889–10902



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Benzofused seven-membered heterocycles such as 1,4-benzo[*e*]diazepines (1,4-BZDs) and 1,4-benzo[*e*]oxazepines (1,4-BZOs) were efficiently synthesized by Rh-catalyzed hydrofunctionalization of internal alkynes and allenes in good to excellent yields. The asymmetric hydroamination of (aminomethyl)anilines gave rise to 3-vinyl-1,4-BZDs with excellent enantioselectivities. Orthogonal *N*-deprotection of 1,4-BZDs allowed an easy entry to an advanced pyrrolobenzodiazepine metabolite of the V₂-receptor antagonist Lixivaptan.



Benzofused seven-membered rings containing two heteroatoms (N, O) comprise the structural core of a privileged family of drugs employed to treat several indications.¹ 1,4-Benzo[*e*]diazepines (1,4-BZDs) are known to interact with a variety of human receptors² and have been extensively used to treat Central Nervous System (CNS) illnesses,³ cancer,⁴ or HIV virus.⁵ In addition, several drugs and advanced metabolites possess a stereodefined chiral Csp³ in C-3 (1,4 benzodiazepine numbering), which enhances their biological activity,⁶ e.g., the pyrrolobenzodiazepines (PBZDs),⁷ bearing a [7,5] ring fusion with an *N*-bridgehead (Figure 1). On the other hand, 1,4-benzo[*e*]oxazepines (1,4-BZOs) possess recognized pharmacological activity in the treatment of Alzheimer disease⁸ and as tranquilizers.⁹

These highly relevant biological activities of 1,4-BZDs have inspired chemists over the years to develop a variety of synthetic approaches based on Friedel–Crafts reactions,¹⁰ ring expansions,¹¹ aza-Michael cyclizations,¹² click chemistry,¹³ heteroannulations,¹⁴ Ugi condensations,¹⁵ or 1,5-hydride

transfer cyclization reactions.¹⁶ Although all of these strategies could be considered very useful to build the azaheterocycle skeleton, they lack the capacity to introduce stereodefined Csp³ formation in C-3, e.g., a chiral allylic/homoallylic amine (Figure 1)

In this regard, transition metal-catalyzed asymmetric hydrofunctionalization/cyclization of allenes/internal alkynes has been used as an eco-friendly strategy to afford enantioenriched five- and six-membered heterocycles from achiral starting materials.¹⁷ The combination with a catalytic amount of Brønsted acids allows the π -allyl intermediate formation that can be subsequently trapped with *N*- and *O*-nucleophiles to afford the corresponding chiral allylic amine or allyl ether (Scheme 1).¹⁷ This methodology was pioneered by Yamamoto (Scheme 1a),¹⁸ who was able to obtain a racemic five-membered ring in a Pd-catalyzed hydroamidation of allenes,^{18a} and later the enantioenriched five- and six-membered rings in a Pd-catalyzed hydroamidation of internal alkynes.^{18b} The groups of Toste, Liu, and Widenhoefer were working successfully on catalytic Au and Brønsted acid heterocyclizations of allenes (Scheme 1b).¹⁹ Recently, the group of Breit²⁰ has developed an intensive study of the Rh-catalyzed hydrofunctionalizations to afford enantioenriched α -vinylated five- and six-membered azaheterocycles (through NTs nucleophiles)^{20e,f} and tetrahydropyrans (Scheme 1c).^{20g} However, only a single benzofused seven-membered azaheterocycle, 4-vinyl-tetrahydrobenzo[*b*][1,5]-benzoxazepine, could





Figure 1. Bioactive 1,4-benzodiazepines and 1,4-benzoxazepines.

Received: May 31, 2021

Published: July 14, 2021




Scheme 1. Rh-Catalyzed Hydrofunctionalizations of Alkynes and Allenes to α -Vinylated Heterocycles

be synthesized in low chemical yield but good ee using the same protocol.²¹ Herein, we report a Rh-catalyzed hydrofunctionalization of internal alkynes and allenenes to benzofused seven-membered heterocycles employing substrates bearing N–Ar groups as nitrogenated nucleophiles.^{21g} The enantioselective hydroamination to 3-vinyl-1,4-BZDs and hydroalkoxylation to 3-vinyl-1,4-BZO is conveniently disclosed (Scheme 1).


We began our study exploring the virtually unknown intramolecular Rh-catalyzed hydrofunctionalizations of internal alkynes to seven-membered heterocycles (Scheme 2). Gratify-

Scheme 2. Rh-Catalyzed Hydrofunctionalizations of Internal Alkynes 1a–d to Seven-Membered Heterocycles 2a–d



ingly, benzylic alcohol **1a** (X = O, Z = NTs) smoothly cyclized, under standard conditions,^{20a} to the corresponding 3-vinyl-1,4-benzoxazepine **2a** in very good yield. On changing the nature of the heteroatoms, using oxygen as alkyne tether and PMP-protected amine as a nucleophile, **1b** (X = NPMP, Z = O), the heterocyclization efficiency to **2b** dropped to 41% yield. In this case, partial depropargylation of starting material was detected, whereas when the carbon-tethered alkynylamine **1c** (X = NPMP, Z = CH₂) was used, the corresponding α -vinyl-2-benzazepine **2c** was isolated in a moderate 57% yield.²³ To our delight, when both the nucleophile and the alkyne tether were nitrogen atoms, **1d** (X = NPMP, Z = NBoc), the hydroamination smoothly occurred to give the desired 3-vinyl-1,4-BDZ **2d** in fairly good yield.

To accomplish our synthetic goal, we then proceeded to evaluate the Rh-catalyzed asymmetric hydroamination of **1d** (Table 1), with a slight modification of our previous conditions regarding reactants loadings and temperature.


Table 1. Optimization of Rh-Catalyzed Asymmetric Hydroamination of Internal Alkynes **1d** and **1e**

entry ^a	alkyne 1	chiral ligand (L*)	Brønsted acid	1,4-BDZ 2 yield (%)	er
1	1d	Josiphos-SL-J002–1	<i>rac</i> -BNP acid	<5	
2	1d	(<i>R</i>)-BINAP	PPTS	traces	
3	1d	(<i>R</i>)-BINAP	<i>rac</i> -BNP acid	19	57:43
4 ^b	1d	(<i>R</i>)-BINAP	<i>rac</i> -BNP acid	58	57:43
5	1d	(<i>R</i>)-DTBM-Segphos	<i>rac</i> -BNP acid	73	57:43
6	1d	(<i>S</i>)-DTBM-Garphos	<i>rac</i> -BNP acid	81	67:33 ^c
7	1e	(<i>R</i>)-DTBM-Garphos	TFA	50	80:20
8 ^d	1e	(<i>R</i>)-DTBM-Garphos	TFA	60	60:40

^aReaction conditions: 4 mol % [Rh(cod)Cl]₂, 10 mol % L*, 10 mol % Brønsted acid, DCE (0.4 M). ^b5 days. ^cThe (*S*)-**2d** was observed as a major enantiomer. ^dReaction performed at 70 °C. PMP = *p*-methoxyphenyl).

Using Josiphos-SL-J002–1, a member of the typical family of chiral ligands for intramolecular asymmetric hydroaminations,^{20e} only gave traces of **2d** (Table 1, entry 1). When (*R*)-BINAP was used as chiral ligand, 3-vinyl-1,4-benzodiazepine **2d** could only be obtained in a low 19% yield and 57:43 er in the presence of *rac*-BNP as Brønsted acid (Table 1, entries 2 and 3). The yield increased to 58%, without any erosion of enantioselectivity, when the reaction was run for 5 days at the same temperature (Table 1, entry 4). Pleasingly, when chiral biaryl phosphine ligands (*R*)-DTBM-Segphos and (*S*)-DTBM-Garphos were used (Table 1, entries 5 and 6), good yields and promising enantioselectivities of **2d** (73–81%, 14–34% ee) were obtained.²⁴ We reasoned that a more rigid *N*-protecting group (e.g., tosyl group) might help to increase the enantioselectivity of the hydroamination. In fact, when **1e** (PG = Ts) was used in the presence of (*R*)-DTBM-Garphos as chiral ligand and TFA as Brønsted acid (pK_a = 0.52), the corresponding 3-vinyl-1,4-benzodiazepine **2e** was obtained in 50% yield and 80:20 er (Table 1, entry 7).²⁵ Unfortunately, reaction at a higher temperature, 70 °C, had limited effect in yield with quite considerable erosion of enantioselectivity (Table 1, entry 8).²⁴

The fact that the best result regarding the enantioselectivity was 60% made us wonder about the influence of the Brønsted acid in the isomerization process of the internal alkyne to the terminal allene. So, we decided to directly synthesize allenes **3d** and **3e** to make them react under the optimized conditions (Table 2). Unfortunately, when using chiral biaryl phosphine ligands (*R*)-DTBM-Segphos and (*R*)-DTBM-Garphos, allene


Table 2. Optimization of Rh-Catalyzed Asymmetric Hydroamination of Allenes **3d** and **3e**

entry ^a	allene 3	chiral ligand (L*)	Brønsted acid	1,4-BDZ 2 yield (%)	er
1	3d	(<i>R</i>)-DTBM-Segphos	<i>rac</i> -BNP acid	50	74:26
2	3d	(<i>R</i>)-DTBM-Garphos	<i>rac</i> -BNP acid	76	75:25
3 ^b	3d	(<i>R</i>)-DTBM-Garphos	<i>rac</i> -BNP acid	70	78:22
4	3e	(<i>R</i>)-DTBM-Segphos	PPTS	80	90:10
5	3e	(<i>R</i>)-DTBM-Garphos	PPTS	70	95:5
6	3e	(<i>R</i>)-DTBM-Garphos	ClCH ₂ CO ₂ H	90	91:9
7 ^c	3e	(<i>R</i>)-DTBM-Garphos	PPTS	60	95:5

^aReaction conditions: 4 mol % [Rh(cod)Cl]₂, 10 mol % L*, 10 mol % Brønsted acid, DCE (0.4 M). ^b0.2 M instead of 0.4 M. ^c70 °C. PMP = *p*-(methoxyphenyl).

3d gave rise to 3-vinyl-1,4-benzodiazepine **2d** in moderate to good yields with modest enantioselectivities (Table 2, entries 1–3). Interestingly, hydroaminations occurred more efficiently in terms of chemical yields and enantioselectivities with the more rigid tosylated allene **3e**. Under standard conditions with PPTS as Brønsted acid ($pK_a = 5.21$) and (*R*)-DTBM-Segphos as chiral ligand, the 3-vinyl-1,4-benzodiazepine **2e** could be obtained in 80% yield and 90:10 er (Table 2, entry 4).²⁶ To our delight, upon changing the nature of the chiral ligand to (*R*)-DTBM-Garphos, the 1,4-BDZ **2e** could be obtained in 70% yield with an excellent 95:5 er (Table 2, entry 5). Curiously, the employment of chloroacetic acid ($pK_a = 2.87$) favors the reaction to give an excellent yield (90%) but with slight erosion of enantioselectivity (91:9 er, Table 2, entry 6). Conversely, when the reaction was performed at a higher temperature, 70 °C, a lower chemical yield was obtained (60%) but without loss of enantioselectivity (95:5 er, Table 2, entry 7).²⁴ This result contrasts with the drop of ee when using the alkyne **1e** at 70 °C (Table 1, entry 8). We speculate that the nature of the Brønsted acid is crucial (PPTS vs TFA) to favor a cationic intermediate (with PPTS) that would evolve via an “outer sphere” mechanism rather than a more neutral-like intermediate (with TFA) that might favor competitive mechanisms that would erode the enantioselectivity of the process.

Having established the optimized conditions, a series of *N*-benzylamino *N*-tosyl allenes **3** bearing different substituents on the benzene ring were screened (Scheme 3).²⁷ All of the tested substrates bearing strong EDG and EWG (OMe, CF₃), halogens (F, Cl, Br), or alkyl (Me) groups in any position of the ring are well tolerated to give the corresponding 3-vinyl-1,4-BDZs **2f**–**2n** in rather good yields and excellent enantiomeric ratios, indicating that the electronic properties of the aromatic moiety have little influence on the reactivity and enantioselectivity. By contrast, the asymmetric reaction was very sensitive to the nature of the nucleophile since the

Scheme 3. Scope of the Asymmetric Rh-Catalyzed Hydrofunctionalizations of Allenes **3**


^aPPTS. ^bClCH₂CO₂H

hydroxylated allene **3a** smoothly cyclized to the 3-vinyl-1,4-benzodiazepine **2a** (90% yield) but with a moderate 78:22 er.

From the literature²⁸ and our own observations/results during the screening of the reaction conditions, we cannot anticipate which one of the two competing pathways typically proposed for Rh-catalyzed hydrofunctionalizations based on “inner” (reductive elimination) or “outer” (external nucleophile attack) is operating.^{19,20} The nature of the nucleophile plays a crucial role in the last C–X (N, O) bond formation (hydroamination vs hydroalkoxylation). Thus, when NHPMP acts as a nucleophile, an S_N2 attack over the Rh- π -allyl complex may occur (“outer sphere”).²⁹ On the other hand, alcohols typically follow a reductive elimination when they act as a nucleophile (“inner sphere”), and this may cause the low enantioselectivity found in the cyclization of benzylic alcohol **3a**.³⁰

We next turned toward derivatization of the enantioenriched 3-vinyl-1,4-benzodiazepine obtained (Scheme 4). Orthogonal *N*-deprotection of the PMP group of **2e** was carried under typical oxidative cleavage conditions (CAN in a mixture of MeCN/H₂O) to give rise to the desired benzylammonium salt **4** in 85% yield.³¹ On the other hand, removal of the Ts group of **2e** could be achieved using mild reducing conditions (Na, naphthalene, rt) to afford the aniline **5** in 85% yield.³² The benzylammonium salt **4** reacted smoothly with acryloyl chloride to afford amide **6** in 65% yield. Finally, an RCM (Hoveyda–Grubbs catalyst second G, 87%) gave rise to the pyrrol-2-one ring **7**, which is an advanced metabolite of Lixivaptan, a vasopressin V₂-receptor antagonist to treat congestive heart failure and liver cirrhosis.^{7a,33} The derivatization process occurred without erosion of enantioselectivity (94:6 er).

In summary, we have developed an intramolecular Rh-catalyzed hydrofunctionalization of internal alkynes and allenes to benzofused seven-membered heterocycles. The asymmetric hydroamination of (aminomethyl)aniline derivatives afforded chiral 3-vinyl-1,4-benzodiazepines (1,4-BZDs) with good to excellent yields and enantioselectivities. Orthogonal *N*-deprotection of 1,4-BZDs allowed an easy manipulation that

Scheme 4. Derivatization of 3-Vinyl-1,4-benzodiazepine **2e**^a

^aConditions: (a) 2.5 equiv of CAN, MeCN/H₂O, then HCl (1 M) in Et₂O, 85% yield; (b) 6 equiv of Na, 0.2 equiv of naphthalene, THF, rt, 16 h, 85% yield; (c) 2 equiv of acryloyl chloride, 2 equiv of Et₃N, 0.1 equiv of DMAP, DCM, 0 °C to rt, 2 h, 65% yield; (d) 10 mol % Hoveyda–Grubbs catalyst second G, DCM, reflux, 36 h, 87% yield.

led to an enantioenriched advanced metabolite of the V₂-receptor antagonist Lixivaptan. Mechanistic investigations are currently underway in our laboratory.

EXPERIMENTAL SECTION

General Information. All reactions were performed under an inert atmosphere of argon and with anhydrous solvents in a glassware oven or flame-dried at 80 °C unless otherwise stated. All chemicals were purchased from Acros Organics Ltd., Aldrich Chemical Co. Ltd., Alfa Aesar, Strem Chemicals Inc., Fluorochem Ltd., or TCI Europe N.V. chemical companies and used without further purification, unless otherwise stated. Analytical thin-layer chromatography was carried out on silica-coated aluminum plates (silica gel 60 F₂₅₄ Merck) or on aluminum sheets (aluminum oxide 60 F₂₅₄ neutral Merck) using UV light as a visualizing agent (254 nm) and KMnO₄ (solution of 1.5 g of potassium permanganate, 10 g of potassium bicarbonate and 1.25 mL of 10% sodium hydroxide in 200 mL of water) with heat as developing agents. Flash column chromatography was performed on silica gel 60 (Merck, 230–400 mesh) with the indicated eluent. All other reagents and solvents (acetonitrile, dichloromethane, dichloroethane, tetrahydrofuran, toluene, and methanol) were used dry, unless otherwise indicated.

Enantiomeric ratio (er) values were determined on an Agilent HPLC 1100 Series or on a Jasco SFC 4000 series using commercially available chiral columns.

¹H NMR, ¹³C NMR, and DEPT experiments were carried out using a Varian Inova 500, Varian Inova 400 MHz or Varian Mercury 300 MHz. All NMR experiments were recorded at 298 K unless otherwise stated. All chemical shifts are reported in parts per million (ppm) and referenced to residual solvent peaks. Coupling constants (*J*) are given in hertz (Hz). Multiplicities are reported as follows: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet or as a combination of them. The proton signals corresponding to NH and OH groups may not appear in the ¹H NMR spectra due to deuterium exchange.

Reactions were followed using a GC Agilent HP-6890N with a mass spectroscopy HP-5973N using DB-35MS and HP-5MS columns for the GC and a chemical ionization font for the MS. Mass spectrometry analysis was carried out using a Micromass Autospec, a TRACE MS, or a HP-5988-A with chemical ionization and a Bruker Microtof APCI using chemical ionization spectrometers at the CACTUS Facility (Universidade de Santiago de Compostela).

X-ray crystallographic analysis was performed at the CACTUS facility of the University of Santiago de Compostela.

General Procedure for the Preparation of Alkynes **1a, **1d**, and **1e**.** *PG-Amine Protection.* Boc₂O (9.3 g, 42 mmol, 1.7 equiv), DMAP (0.92 g, 7.5 mmol, 0.3 equiv), and Et₃N (3.5 mL, 25 mmol, 1 equiv) were added at rt to a solution of ethyl 2-aminobenzoate (4.13 g, 25 mmol, 1 equiv) in 250 mL of dry THF (0.1 M), and the reaction mixture was then stirred at 60 °C in an oil bath for 24 h. Then the reaction was quenched at rt with H₂O, and both layers were separated. The aqueous layer was extracted with Et₂O (3 × 50 mL), and the combination of organic layers was washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The compound **S1a** was purified by silica gel column chromatography with hexane/EtOAc (39:1) as the eluent.

The Ts-derivative **S1b** was synthesized according to the literature.³⁴

Ethyl 2-((tert-Butoxycarbonyl)amino)benzoate (S1a**):** 70% yield (5.57 g, 21 mmol); amorphous white solid; ¹H NMR (300 MHz, CDCl₃) δ 10.30 (s, 1H), 8.47–8.41 (m, 1H), 8.01 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.55–7.46 (m, 1H), 6.99 (ddd, *J* = 8.3, 7.3, 1.2 Hz, 1H), 4.37 (q, *J* = 7.2 Hz, 2H), 1.53 (d, *J* = 0.9 Hz, 8H), 1.44–1.37 (m, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.0, 152.8, 142.3, 134.3, 130.8, 120.9, 118.6, 114.5, 80.3, 61.1, 28.3, 14.2; MS (CI), *m/z* (%) 266 (*M*⁺ + 1, 100).

***N*-Alkylation.**³⁵ A round-bottomed flask equipped with a stirring magnetic bar was flame-dried under a vacuum and backfilled with argon. Then, it was charged with NaH (1.2 equiv), put under a vacuum, and backfilled with argon for three times. Then DMF (0.33 M) was added, and the mixture was cooled to 0 °C. A solution of *N*-protected aniline **S2** (1 equiv) in DMF (2 mL) was then added slowly, and the mixture was stirred at 0 °C for 2 h. Afterward, a propargyl bromide derivative (1.3 equiv) was added, and the reaction was allowed to warm slowly to rt and stirred for 16 h. The reaction was quenched with a saturated solution of NH₄Cl (aq) and extracted with EtOAc. The aqueous layer was extracted with EtOAc, and the combination of organic layers was washed with a saturated solution of NH₄Cl (aq) (3 × 100 mL). The combination of organic layers was dried over Na₂SO₄ and concentrated in vacuo. The residue was then purified by silica gel column chromatography with hexanes/EtOAc (8:2) as the eluent to give the desired products **S2**.

Ethyl 2-((*N*-2-yn-1-yl)(*tert*-butoxycarbonyl)amino)benzoate (S2d**):** 93% yield (2.95 g, 9.3 mmol); colorless oil; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.91 (d, *J* = 7.7 Hz, 1H), 7.58–7.22 (m, 3H), 4.69 (d, *J* = 17.5 Hz, 1H), 4.41–4.20 (m, 2H), 3.96 (d, *J* = 17.4 Hz, 1H), 1.75 (s, 3H), 1.51 (s, 3H), 1.35 (t, *J* = 7.0 Hz, 3H), 1.28 (s, 6H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 163.2, 133.0, 132.4, 131.6, 131.0, 130.3, 129.8, 128.8, 127.1, 80.3, 74.9, 61.1, 39.5, 28.0, 14.1, 3.6; MS (CI), *m/z* (%) 318 (*M*⁺ + 1, 100).

Ethyl 2-((*N*-2-yn-1-yl)-4-methylphenyl)sulfonamido)benzoate (S2e**):** 90% yield (3.34 g, 9 mmol); amorphous off-white solid; ¹H NMR (300 MHz, CDCl₃) δ 7.89–7.81 (m, 1H), 7.64–7.56 (m, 2H), 7.45–7.36 (m, 2H), 7.26–7.19 (m, 2H), 7.17–7.10 (m, 1H), 4.54 (s, 1H), 4.28 (q, *J* = 7.1 Hz, 2H), 2.41 (s, 3H), 1.69 (t, *J* = 2.4 Hz, 3H), 1.37 (t, *J* = 7.1 Hz, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.1, 143.1, 137.9, 137.4, 133.0, 131.8, 131.5, 131.1, 129.1, 128.7, 127.8, 81.5, 74.0, 61.4, 42.0, 21.5, 14.1, 3.4; MS (CI), *m/z* (%) 372 (*M*⁺ + 1, 100).

Ester Reduction.³⁶ DIBAL-H (1 M in DCM, 2.2 equiv) was added dropwise to a stirred solution of the ester **S2** (1 equiv) in DCM (0.3 M) at –78 °C. The reaction was then stirred at that temperature for 3 h. Afterward, MeOH (5 mL) was added followed by a saturated solution of the Rochelle Salt at –78 °C. The reaction was then warmed up to rt and stirred for 1 h. The mixture was extracted with DCM (3 × 30 mL), and the combination of organic layers was washed with a saturated solution of NaCl (aq), dried over Na₂SO₄, and concentrated in vacuo. The residue was then purified by silica gel column chromatography with hexanes/EtOAc (9:1 to 7:3) as the eluent to afford the desired product **S3d/1a**.

tert-Butyl But-2-yn-1-yl(2-((hydroxymethyl)phenyl)carbamate (**S3d**): 99% yield (2.53 g, 9.2 mmol); amorphous white solid. It was used in the next step without further purification.

N-(But-2-yn-1-yl)-*N*-(2-((hydroxymethyl)phenyl)-4-methylbenzenesulfonamide (**1a**): 91% yield (2.8 g, 8.5 mmol); amorphous off-white solid; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.64–7.55 (m, 3H), 7.37 (td, $J = 7.5, 1.3$ Hz, 1H), 7.33–7.23 (m, 2H), 7.15 (td, $J = 7.7, 1.7$ Hz, 1H), 6.65 (dd, $J = 8.0, 1.3$ Hz, 1H), 4.93 (s, 1H), 4.60 (s, 1H), 4.33 (s, 2H), 3.00–2.89 (m, 1H), 2.45 (s, 3H), 1.65 (t, $J = 2.4$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 144.0, 142.2, 137.3, 135.2, 131.0, 129.4, 129.3, 128.3, 128.3, 128.2, 82.0, 72.8, 61.3, 42.6, 21.6, 3.4; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$ [$\text{M} - \text{H}_2\text{O}$] $^+$ 312.1053, found 312.1059.

Alcohol Oxidation. DMP (1.1 equiv) was added to a stirred solution of the alcohol **S3d/1a** (1 equiv) in DCM (0.25 M) at rt. The mixture was stirred for 30 min. The reaction was quenched with a 1 M solution of NaOH (aq) and extracted with DCM (2 \times 30 mL). The combination of organic layers was washed with brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was used in the next step without further purification.

Reductive Amination. *p*-Anisidine (1.5 equiv) was added to a stirred solution of the aldehyde previously synthesized in MeOH (0.25 M) or (1:1 MeOH/DCM) under an argon atmosphere. The reaction was stirred at room temperature for 18 h. Then the reaction was cooled to 0 $^\circ\text{C}$, and NaBH_4 (1.1 equiv) was added portionwise. The reaction was then allowed to warm up to rt and stirred for 2 h. The reaction was quenched with water and extracted with DCM. The combination of organic layers was washed with brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was then purified by silica gel column chromatography with hexanes/EtOAc (9:1 to 8:2) as the eluent to give the desired products **1d/1e**.

tert-Butyl But-2-yn-1-yl(2-(((4-methoxyphenyl)amino)methyl)phenyl)carbamate (**1d**): 80% yield; amorphous off-white solid; $^1\text{H NMR}$ (300 MHz, $\text{DMSO}-d_6$, 80 $^\circ\text{C}$) δ 7.46–7.35 (m, 1H), 7.31–7.18 (m, 3H), 6.7 (d, $J = 8.9$ Hz, 2H), 6.5 (d, $J = 8.9$ Hz, 2H), 5.46 (bs, 1H), 4.30 (bs, 2H), 4.21 (bs, 2H), 3.64 (s, 3H), 1.75 (t, $J = 2.4$ Hz, 3H), 1.39 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, $\text{DMSO}-d_6$, 80 $^\circ\text{C}$) δ 153.0, 150.7, 142.7, 139.5, 137.6, 127.5, 127.1, 126.9, 126.8, 114.5, 113.0, 79.5, 79.4, 75.0, 55.2, 43.3, 39.3, 27.6, 2.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$ 381.2173, found 381.2171.

N-(But-2-yn-1-yl)-*N*-(2-(((4-methoxyphenyl)amino)methyl)phenyl)-4-methylbenzenesulfonamide (**1e**): 70% yield (2 g, 4.8 mmol); amorphous off-white solid; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.64 (d, $J = 7.9$ Hz, 2H), 7.52 (d, $J = 7.7$ Hz, 1H), 7.29 (d, $J = 8.1$ Hz, 3H), 7.13 (t, $J = 7.7$ Hz, 1H), 6.76 (t, $J = 7.1$ Hz, 3H), 6.62 (d, $J = 8.4$ Hz, 2H), 4.52 (s, 2H), 4.33 (s, 2H), 4.08–4.01 (m, 1H), 3.74 (s, 3H), 2.45 (s, 3H), 1.65 (t, $J = 2.4$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 152.1, 143.8, 142.6, 141.1, 137.7, 135.8, 129.4, 129.3, 129.1, 128.4, 127.4, 114.9, 114.3, 81.8, 73.0, 55.8, 45.4, 42.3, 21.6, 3.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 435.1737, found 435.1730.

Preparation of Alkyne 1b. 2-(But-2-yn-1-yloxy)benzaldehyde (**S4**). To a suspension of K_2CO_3 (1 g, 7.2 mmol, 1.2 equiv) in DMF (3 mL) at rt was added salicylaldehyde (0.63 mL, 6 mmol, 1 equiv) followed by 1-bromo-2-butyne (0.58 mL, 6.6 mmol, 1.1 equiv). The mixture was then stirred at rt for 16 h. The reaction was quenched with water (10 mL). The aqueous layer was extracted with AcOEt (3 \times 10 mL), and the combination of organic layers was washed with water (3 \times 10 mL), brine (2 \times 10 mL), dried over Na_2SO_4 , and concentrated in vacuo. The residue was purified by silica gel column chromatography with hexanes/EtOAc (19:1) as the eluent to give **S6**: 83% yield (870 mg, 5 mmol); colorless oil; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 10.46 (s, 1H), 7.82 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.53 (td, $J = 7.3, 1.8$ Hz, 1H), 7.09 (d, $J = 8.5$ Hz, 1H), 7.06–7.00 (m, 1H), 4.76 (q, $J = 2.3$ Hz, 2H), 1.83 (t, $J = 2.3$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 189.7, 160.1, 135.7, 128.3, 125.4, 121.2, 113.4, 84.7, 73.3, 57.1, 3.6; MS (CI), m/z (%) 175 ($\text{M}^+ + 1$, 100).

N-(2-(But-2-yn-1-yloxy)benzyl)-4-methoxyaniline (**1b**). used the general procedure for reductive amination, 70% yield (983 mg, 3.5

mmol); yellow oil; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.32 (d, $J = 7.4$ Hz, 1H), 7.25 (td, $J = 7.9, 7.5, 1.5$ Hz, 1H), 7.00 (d, $J = 8.2$ Hz, 1H), 6.95 (td, $J = 7.4, 0.9$ Hz, 1H), 6.81–6.73 (m, 2H), 6.68–6.61 (m, 2H), 4.72 (q, $J = 2.3$ Hz, 2H), 4.32 (s, 2H), 3.74 (s, 3H), 1.87 (t, $J = 2.3$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 152.3, 148.6, 139.2, 125.6, 124.8, 124.6, 117.7, 111.3, 111.0, 108.5, 80.1, 70.7, 53.0, 52.2, 40.8, 0.0; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{18}\text{H}_{20}\text{NO}_2$ [$\text{M} + \text{H}$] $^+$ 282.1489, found 282.1492.

Preparation of Alkyne 1c. 1-(Diethoxymethyl)-2-iodobenzene (**S5**). Synthesized according to the literature.³⁷

3-(2-(Diethoxymethyl)phenyl)propanal (**S6**). Iodide **S5** (5.73 g, 18.7 mmol, 1 equiv) and the allylic alcohol (3.18 mL, 46.8 mmol, 2.5 equiv) were added to a solution of $\text{Pd}(\text{OAc})_2$ (168 mg, 0.75 mmol, 4 mol %), NaHCO_3 (7.54 g, 89.8 mmol, 4.8 equiv), and Bu_4NCl (5.2 g, 18.7 mmol, 1 equiv) in DMF (35 mL). The mixture was stirred at 50 $^\circ\text{C}$ in an oil bath for 4 h, and the reaction was filtered through a short plug of silica gel. Then, H_2O (30 mL) was added to the filtrate and then extracted with EtOAc (2 \times 50 mL). The combination of organic layers was washed with H_2O (2 \times 50 mL) and brine (50 mL), dried over Na_2SO_4 , and concentrated in vacuo. The product was purified by silica gel column chromatography with hexanes/EtOAc (19:1) as the eluent to give the aldehyde **S6**: 86% yield (3.8 g, 16.1 mmol); yellow oil; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 9.83 (t, $J = 1.4$ Hz, 1H), 7.55 (dd, $J = 7.3, 2.0$ Hz, 1H), 7.30–7.20 (m, 2H), 7.17 (dd, $J = 7.0, 1.6$ Hz, 1H), 5.56 (s, 1H), 3.70–3.42 (m, 6H), 3.07 (t, $J = 7.7$ Hz, 2H), 2.84–2.73 (m, 2H), 1.22 (t, $J = 7.1$ Hz, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 201.8, 138.7, 136.5, 129.6, 128.6, 127.1, 126.1, 100.6, 61.7, 45.4, 24.5, 15.2; MS (CI), m/z (%) 237 ($\text{M}^+ + 1$, 100).

1-(But-3-yn-1-yl)-2-(diethoxymethyl)benzene (**S7**). $n\text{BuLi}$ (7.73 mL, 19.32 mmol, 1.2 equiv) was added dropwise to a solution of DIPA (2.71 mL, 19.32 mmol, 1.2 equiv) in THF (130 mL) at -78 $^\circ\text{C}$. The reaction mixture was warmed to 0 $^\circ\text{C}$ and stirred for 15 min. Then the reaction was cooled to -78 $^\circ\text{C}$, and trimethylsilyldiazomethane (8.05 mL, 16.1 mmol, 1 equiv) was added. The reaction was stirred at -78 $^\circ\text{C}$ for 30 min. Then a solution of aldehyde **S6** (3.8 g, 16.1 mmol, 1 equiv) in THF (33 mL) was added. The mixture was stirred for 1 h, and then the reaction was heated to reflux for 3 h. The reaction was quenched with H_2O (100 mL), and the aqueous layer was extracted with Et₂O (2 \times 60 mL). The combination of organic layers was washed with H_2O (100 mL), dried over Na_2SO_4 , and concentrated in vacuo. The residue was purified by silica gel column chromatography with hexanes/EtOAc (99:1) as the eluent to give **S7**: 51% yield (1.92 g, 8.26 mmol); colorless oil; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.57 (d, $J = 7.6$ Hz, 1H), 7.33–7.17 (m, 3H), 5.61 (s, 1H), 3.70–3.43 (m, 4H), 2.98 (t, $J = 7.7$ Hz, 2H), 2.51 (td, $J = 7.7, 2.7$ Hz, 12H), 1.99 (t, $J = 2.7$ Hz, 1H), 1.24 (t, $J = 7.0$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 138.6, 136.5, 129.8, 128.4, 126.8, 126.2, 100.3, 84.1, 68.8, 61.7, 20.2, 15.2; MS (CI), m/z (%) 233 ($\text{M}^+ + 1$, 100).

1-(Diethoxymethyl)-2-(pent-3-yn-1-yl)benzene (**S8**). $n\text{BuLi}$ (3.2 mL, 8 mmol, 1.1 equiv) was added dropwise at -78 $^\circ\text{C}$ to a solution of **S7** (1.7 g, 7.3 mmol, 1 equiv) in THF (0.3 M). The mixture was stirred for 50 min at -78 $^\circ\text{C}$, then MeI (2.27 mL, 36.5 mmol, 5 equiv) was added, and the reaction was stirred at rt for 16 h. The reaction was quenched with a saturated solution of NH_4Cl (aq). The aqueous layer was extracted with EtOAc (40 mL), and the combination of organic layers was washed with brine (100 mL), dried over Na_2SO_4 , and concentrated in vacuo. The residue was purified by silica gel column chromatography with hexanes/EtOAc (99:1) as the eluent to give **S8**: 92% yield (1.65 g, 6.7 mmol); colorless oil; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.58 (dd, $J = 7.9, 1.8$ Hz, 1H), 7.35–7.16 (m, 3H), 5.63 (s, 1H), 3.67–3.45 (m, 4H), 2.92 (t, $J = 7.7$ Hz, 2H), 2.55–2.33 (m, 2H), 1.78 (t, $J = 2.6$ Hz, 3H), 1.23 (t, $J = 7.1$ Hz, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 139.1, 136.5, 129.6, 128.3, 126.6, 126.0, 100.1, 78.8, 76.0, 61.6, 31.7, 20.6, 15.2, 3.5; MS (CI), m/z (%) 247 ($\text{M}^+ + 1$, 100).

2-(Pent-3-yn-1-yl)benzaldehyde (**S9**). A mixture of **S8** (1.65 g, 6.7 mmol, 1 equiv) and PPTS (505 mg, 2.01 mmol, 0.3 equiv) in acetone (260 mL) and H_2O (7 mL) was heated to reflux in an oil bath for 15 h. The volatiles were removed under a vacuum, the residue was

dissolved in DCM (30 mL), and the solution was washed with H₂O (30 mL). The aqueous layer was extracted with DCM (3 × 20 mL), and the combination of organic layers was washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified by silica gel column chromatography with hexanes/EtOAc (98:2) as the eluent to give **S9**: 94% yield (1.08 g, 6.3 mmol); colorless oil; ¹H NMR (300 MHz, CDCl₃) δ 10.26 (s, 1H), 7.84 (d, J = 7.6 Hz, 1H), 7.51 (t, J = 7.1 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 3.19 (t, J = 7.2 Hz, 2H), 2.58–2.29 (m, 2H), 1.71 (t, J = 2.5 Hz, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 192.0, 143.3, 134.1, 133.7, 131.6, 131.2, 126.9, 77.8, 77.4, 31.5, 21.0, 3.4; MS (CI), *m/z* (%) 173 (M⁺ + 1, 100).

4-Methoxy-N-(2-(pent-3-yn-1-yl)benzyl)aniline (1c): used general procedure for reductive amination, 85% yield (1.5 g, 5.4 mmol); amorphous off-white solid; ¹H NMR (300 MHz, CDCl₃) δ 7.41 (d, J = 7.2 Hz, 1H), 7.32–7.19 (m, 3H), 6.89–6.80 (m, 2H), 6.71–6.60 (m, 2H), 4.31 (s, 2H), 3.79 (s, 3H), 3.69 (bs, 1H), 2.94 (t, J = 7.5 Hz, 2H), 2.51 (ddt, J = 7.5, 5.1, 2.6 Hz, 2H), 1.82 (t, J = 2.6 Hz, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 152.2, 142.7, 139.3, 137.1, 129.5, 128.9, 127.6, 126.7, 115.0, 114.0, 78.7, 76.5, 55.8, 46.9, 31.7, 20.6, 3.6; HRMS (MM: ESI-APCI+) *m/z* calcd for C₁₉H₂₂N₂O [M + H]⁺ 280.1696, found 280.1701.

General Procedure for the Racemic Cyclization of Alkynes 1. A 5 mL sealed tube equipped with stirring magnetic bar was flamed-dried under a vacuum, cooled to rt, and backfilled with argon. Then it was charged with [Rh(cod)Cl]₂ (4 mg, 8 μmol, 0.04 equiv), *rac*-BNP acid (5.6 mg, 16 μmol, 0.08 equiv), and *rac*-BINAP (10 mg, 16 μmol, 0.08 equiv). Afterward, it was put in a vacuum and backfilled with argon three times. Then 0.5 mL of DCE was added, and the mixture was stirred for 10 min at rt. Finally, the alkyne **1** (0.2 mmol, 1 equiv) was added under a flow of argon, and the mixture was stirred at 70 °C in an oil bath for 24 h. After cooling at rt, the solvent was evacuated in vacuo, and the residue was purified by silica gel column chromatography with EtOAc/Hexanes (1:9) as the eluent to give the desired seven-membered heterocycle **2**.

1-Tosyl-3-vinyl-1,2,3,5-tetrahydrobenzo[e][1,4]oxazepine (2a): 85% yield, colorless oil (amorphous off-white solid at 4 °C); ¹H NMR (300 MHz, CDCl₃) δ 7.65–7.58 (m, 2H), 7.40–7.34 (m, 1H), 7.32–7.18 (m, 5H), 5.74 (ddd, J = 17.4, 10.7, 5.3 Hz, 1H), 5.37 (t, J = 1.5 Hz, 1H), 5.31 (t, J = 1.5 Hz, 1H), 5.22 (t, J = 1.4 Hz, 1H), 5.19 (t, J = 1.5 Hz, 1H), 4.49 (d, J = 13.4 Hz, 1H), 4.38 (dd, J = 15.1, 1.9 Hz, 1H), 4.27–4.13 (m, 1H), 4.17 (d, J = 13.4 Hz, 1H), 2.98 (dd, J = 15.1, 10.3 Hz, 1H), 2.43 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 143.7, 139.7, 138.5, 138.2, 135.1, 129.8, 129.6, 128.9, 128.8, 128.0, 127.1, 117.2, 80.7, 72.2, 55.6, 21.6; HRMS (MM: ESI-APCI+) *m/z* calcd for C₁₈H₁₉NO₃S [M + H]⁺ 330.1158, found 330.1158.

4-(4-Methoxyphenyl)-3-vinyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine (2b): 41% yield, colorless oil; ¹H NMR (300 MHz, CDCl₃) δ 7.23 (dd, J = 7.3, 1.7 Hz, 1H), 7.14 (td, J = 8.0, 1.8 Hz, 1H), 6.99 (td, J = 7.4, 1.3 Hz, 1H), 6.86 (dd, J = 8.1, 1.3 Hz, 1H), 6.75 (d, J = 9.2 Hz, 2H), 6.67 (d, J = 9.2 Hz, 2H), 5.90 (ddd, J = 17.2, 10.4, 4.1 Hz, 1H), 5.44 (dt, J = 17.2, 1.8 Hz, 1H), 5.33 (dt, J = 10.4, 1.8 Hz, 1H), 4.93 (d, J = 17.1 Hz, 1H), 4.61–4.50 (m, 1H), 4.36–4.24 (m, 3H), 3.71 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 158.4, 151.9, 144.6, 133.4, 129.3, 128.1, 127.9, 122.2, 119.4, 116.9, 114.7, 114.3, 72.8, 64.0, 55.8, 48.2; HRMS (MM: ESI-APCI+) *m/z* calcd for C₁₈H₂₀NO₂ [M + H]⁺ 282.1489, found 282.1493.

2-(4-Methoxyphenyl)-3-vinyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine (2c): 57% yield, colorless oil; ¹H NMR (300 MHz, CDCl₃) δ 7.29 (d, J = 6.9 Hz, 1H), 7.24–7.12 (m, 2H), 7.09 (d, J = 6.9 Hz, 1H), 6.75 (d, J = 9.2 Hz, 2H), 6.65 (d, J = 9.2 Hz, 2H), 5.99 (ddd, J = 17.2, 10.4, 3.6 Hz, 1H), 5.28–5.15 (m, 2H), 4.75 (d, J = 17.1 Hz, 1H), 4.36–4.25 (m, 1H), 4.24 (d, J = 17.0 Hz, 1H), 3.72 (s, 3H), 3.04–2.80 (m, 2H), 2.36–2.21 (m, 1H), 2.15–1.96 (m, 1H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 151.1, 144.9, 139.8, 139.4, 137.4, 130.2, 127.8, 126.7, 126.0, 114.8, 114.4, 112.9, 62.0, 55.8, 49.3, 32.5, 32.4; HRMS (MM: ESI-APCI+) *m/z* calcd for C₁₉H₂₂NO [M + H]⁺: 280.1696, found 280.1695.

2-(4-Methoxyphenyl)-3-(prop-1-en-1-yl)-1,2,3,4-tetrahydroisoquinoline (2c'): 20% yield, colorless oil (mixture of isomers); ¹H

NMR mixture of isomers (300 MHz, CDCl₃) δ 7.15–7.02 (m, 4H isom 1, 4H isom 2), 6.91–6.82 (m, 2H isom 1, 2H isom 2), 6.82–6.74 (m, 2H isom 1, 2H isom 2), 5.49–5.22 (m, 1H isom 1, 1H isom 2), 4.55 (dt, J = 8.8, 4.4 Hz, 1H isom 2), 4.41–4.31 (m, 1H isom 2), 4.27 (d, J = 15.5 Hz, 1H isom 1, 1H isom 2), 4.20 (d, J = 15.6 Hz, 1H isom 1, 1H isom 2), 3.71 (s, 3H isom 1, 3H isom 2), 3.17 (dd, J = 15.8, 5.4 Hz, 1H isom 1, 1H isom 2), 2.77 (dd, J = 15.8, 3.1 Hz, 1H isom 1), 2.70 (dd, J = 15.9, 4.3 Hz, 1H isom 2), 1.55 (dd, J = 6.8, 1.6 Hz, 3H isom 2), 1.46 (dt, J = 6.0, 1.1 Hz, 3H isom 1); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 153.7, 152.8, 144.5, 144.1, 134.4, 134.3, 133.6, 133.5, 129.8, 129.3, 128.8, 128.7, 127.4, 126.3, 126.2, 125.9, 125.8, 119.3, 117.5, 114.5, 114.4, 56.9, 55.6, 55.6, 53.0, 49.9, 48.1, 35.3, 34.4, 17.8, 13.4; HRMS (MM: ESI-APCI+) *m/z* calcd for C₁₉H₂₂NO [M + H]⁺ 280.1696, found 280.1695.

tert-Butyl 4-(4-Methoxyphenyl)-3-vinyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-1-carboxylate (2d): 70% yield, amorphous off-white solid; ¹H NMR (300 MHz, DMSO-*d*₆, 80 °C) δ 7.43–7.30 (m, 1H), 7.29–7.09 (m, 3H), 6.70 (d, J = 9.1 Hz, 2H), 6.62 (d, J = 9.1 Hz, 2H), 6.03 (ddd, J = 17.2, 10.5, 4.7 Hz, 1H), 5.42–5.19 (m, 2H), 4.81–4.60 (m, 1H), 4.68 (d, J = 17.3 Hz, 1H), 4.39 (d, J = 17.3 Hz, 1H), 4.07 (dd, J = 14.6, 5.2 Hz, 1H), 3.62 (s, 3H), 3.48 (dd, J = 14.6, 9.9 Hz, 1H), 1.22 (s, 9H); ¹³C{¹H} NMR (75 MHz, DMSO-*d*₆, 80 °C) δ 152.5, 151.2, 143.8, 140.7, 135.3, 132.8, 127.8, 126.9, 125.7, 124.9, 115.4, 114.3, 113.9, 79.3, 59.4, 55.2, 51.3, 48.1, 27.3; HRMS (MM: ESI-APCI+) *m/z* calcd for C₂₃H₂₈N₂O₃Na [M + Na]⁺ 403.1992, found 403.1990.

General Procedure for the Asymmetric Cyclization of Alkynes 1. A 5 mL sealed tube equipped with stirring magnetic bar was flamed-dried under a vacuum, cooled to rt, and backfilled with argon. Then, it was charged with [Rh(cod)Cl]₂ (4 mg, 8 μmol, 0.04 equiv), Brønsted acid (16 μmol, 0.08 equiv), and chiral ligand (16 μmol, 0.08 equiv). Afterward, it was put in a vacuum and backfilled with argon three times. Then, 0.5 mL of DCE was added, and the mixture was stirred for 10 min at rt. Finally, the alkyne **1** (0.2 mmol, 1 equiv) was added under a flow of argon, and the mixture was stirred at 50 °C in an oil bath for 24 h. After cooling at rt and stripping off the solvent, the resulting residue was purified by silica gel column chromatography with EtOAc/Hexanes (1:9) as the eluent to give the desired seven-membered heterocycle **2**.

General Procedure for the Preparation of Allenes 3d–3f, 3h–3j, and 3n. Tosyl derivatives **S 1f**,³⁹ **S 1h**,⁴⁰ **S 1i**,⁴¹ **S 1j**,⁴² and **S 1n**⁴³ were synthesized according to literature procedures.

See the general procedure for N-alkylation of alkynes.

Ethyl 2-((tert-Butoxycarbonyl)(prop-2-yn-1-yl)amino)benzoate (S10d): 94% yield (2.85 g, 9.4 mmol), colorless oil; ¹H NMR (300 MHz, CDCl₃) δ 7.96 (dd, J = 7.7, 1.8 Hz, 1H), 7.65–7.33 (m, 3H), 4.82 (dd, J = 17.7, 2.5 Hz, 1H), 4.34 (dtd, J = 9.7, 7.1, 3.4 Hz, 2H), 4.03 (dd, J = 17.7, 2.5 Hz, 1H), 2.33–2.15 (m, 1H), 1.60 (s, 2H), 1.39 (t, J = 7.2 Hz, 3H), 1.31 (s, 8H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.0, 154.0, 153.7, 141.6, 141.1, 132.6, 132.5, 131.0, 129.8, 129.5, 129.1, 127.3, 81.0, 80.4, 80.0, 79.8, 72.2, 71.8, 61.1, 60.9, 40.2, 39.1, 28.2, 28.0, 14.1; MS (CI), *m/z* (%) 304 (M⁺ + 1, 100).

Ethyl 2-((4-Methyl-N-(prop-2-yn-1-yl)phenyl)sulfonamido)benzoate (S10e): 90% yield (3.2 g, 9 mmol); amorphous yellow solid; ¹H NMR (300 MHz, CDCl₃) δ 7.94–7.83 (m, 1H), 7.66–7.54 (m, 2H), 7.51–7.35 (m, 2H), 7.30–7.13 (m, 3H), 5.02–4.35 (m, 2H), 4.28 (s, 2H), 2.42 (s, 3H), 2.21 (t, J = 2.5 Hz, 1H), 1.37 (t, J = 7.1 Hz, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.0, 143.4, 137.4, 137.1, 132.9, 132.1, 131.9, 131.3, 129.3, 129.0, 127.7, 73.6, 61.5, 41.3, 21.6, 14.1; MS (CI), *m/z* (%) 358 (M⁺ + 1, 100).

Methyl 4-Methyl-2-((4-methyl-N-(prop-2-yn-1-yl)phenyl)sulfonamido)benzoate (S10f): 90% yield (3.21 g, 9 mmol); amorphous off-white solid; ¹H NMR (300 MHz, CDCl₃) δ 7.73 (d, J = 7.9 Hz, 1H), 7.60–7.50 (m, 2H), 7.20 (dd, J = 8.1, 4.0 Hz, 3H), 7.01 (d, J = 1.7 Hz, 1H), 4.64 (s, 1H), 3.69 (s, 3H), 2.38 (s, 3H), 2.28 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.1, 143.3, 143.2, 137.5, 137.2, 133.0, 131.3, 129.7, 129.3, 129.0, 128.9, 127.9, 127.6, 78.9, 73.4, 52.1, 41.3, 21.5, 21.3; MS (CI), *m/z* (%) 358 (M⁺ + 1, 100).

Methyl 2-((4-Methyl-N-(prop-2-yn-1-yl)phenyl)sulfonamido)-4-(trifluoromethyl)benzoate (S10h). 84% yield (1.8 g, 4.5 mmol); amorphous yellow solid; ^1H NMR (300 MHz, CDCl_3) δ 8.0 (d, J = 8.1 Hz, 1H), 7.7 (d, J = 8.1 Hz, 1H), 7.6 (d, J = 8.0 Hz, 2H), 7.4 (s, 1H), 7.3–7.1 (m, 2H), 4.6 (s, 2H), 3.9 (s, 3H), 2.4 (s, 3H), 2.2 (d, J = 2.5 Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 165.5, 144.2, 138.3, 136.5 (d, J = 8.1 Hz), 133.9 (q, J = 33.6 Hz), 131.8, 129.6, 129.1 (d, J = 3.8 Hz), 127.9, 125.8 (d, J = 3.9 Hz), 124.8, 121.2, 74.5, 52.9, 41.3, 21.7; ^{19}F NMR (282 MHz, CDCl_3) δ -63.2; MS (CI), m/z (%) 412 ($\text{M}^+ + 1$, 100).

Methyl 5-Methoxy-2-((4-methyl-N-(prop-2-yn-1-yl)phenyl)sulfonamido)benzoate (S10i). 83% yield (0.62 g, 1.7 mmol); yellow oil; ^1H NMR (300 MHz, CDCl_3) δ 7.6 (d, J = 7.9 Hz, 2H), 7.3 (d, J = 3.0 Hz, 1H), 7.2 (d, J = 7.9 Hz, 2H), 7.1 (d, J = 8.7 Hz, 1H), 6.9 (dd, J = 8.8, 3.1 Hz, 1H), 4.9 (s, 1H), 4.3 (s, 1H), 3.8 (d, J = 13.9 Hz, 6H), 2.4 (s, 3H), 2.2 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 166.3, 159.6, 143.2, 137.3, 133.54, 133.4, 129.9, 129.4, 127.8, 117.8, 116.0, 79.1, 73.6, 55.8, 52.5, 41.5, 21.6; MS (CI), m/z (%) 423 ($\text{M}^+ + 1$, 100).

Methyl 5-Bromo-2-((4-methyl-N-(prop-2-yn-1-yl)phenyl)sulfonamido)benzoate (S10j). 70% yield (2.95 g, 7 mmol); amorphous off-white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.90 (d, J = 2.5 Hz, 1H), 7.48 (dd, J = 8.3, 6.3 Hz, 3H), 7.16 (d, J = 8.1 Hz, 2H), 6.98 (d, J = 8.3 Hz, 1H), 4.49 (s, 1H), 3.71 (s, 3H), 2.33 (s, 3H), 2.16 (t, J = 2.3 Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 164.9, 143.8, 136.8, 136.6, 135.3, 134.2, 134.1, 133.6, 129.5, 127.7, 123.1, 78.5, 74.1, 52.7, 41.2, 21.6. MS (CI), m/z (%) 374 ($\text{M}^+ + 1$, 100).

Methyl 4,5-Dimethoxy-2-((4-methyl-N-(prop-2-yn-1-yl)phenyl)sulfonamido)benzoate (S10n). 99% yield (0.8 g, 1.98 mmol); white foam; ^1H NMR (300 MHz, CDCl_3) δ 7.59 (d, J = 7.9 Hz, 2H), 7.36 (s, 1H), 7.23 (d, J = 7.9 Hz, 2H), 6.67 (s, 1H), 4.88 (s, 1H), 4.27 (s, 1H), 3.90 (s, 3H), 3.70 (d, J = 2.9 Hz, 6H), 2.40 (s, 3H), 2.23 (t, J = 2.5 Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 165.7, 151.5, 148.8, 143.5, 137.4, 131.5, 129.3, 127.9, 123.9, 115.4, 113.2, 79.3, 73.5, 56.2, 56.0, 52.2, 41.4, 21.6; MS (CI), m/z (%) 404 ($\text{M}^+ + 1$, 100).

Homologation of Alkynes to Allenes. CuI (0.5 equiv), $(\text{CHO})_n$ (2.5 equiv), and C_2NH (1.8 equiv) were added to a stirred solution of the alkyne **S10** (1 equiv) in dioxane (0.2 M). The reaction was then heated to reflux in an oil bath for 6 h. Then, the reaction was cooled to rt, and the solvent was removed in vacuo. The residue was dissolved in CHCl_3 (50 mL) and washed with 10% NH_4OH (2×50 mL) and H_2O (2×50 mL). The combination of organic layers was dried over Na_2SO_4 and concentrated in vacuo. The residue was purified by silica gel column chromatography with hexanes/ EtOAc (8:2) as the eluent to give the allenates **S11**.

Ethyl 2-(Buta-2,3-dien-1-yl)(tert-butoxycarbonyl)amino)benzoate (S11d): 82% yield (2.44 g, 7.7 mmol); yellow oil; ^1H NMR (300 MHz, CDCl_3) δ 7.89 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.35–7.17 (m, 2H), 5.30 (p, J = 6.6 Hz, 1H), 4.78–4.60 (m, 2H), 4.58–4.41 (m, 1H), 4.38–4.21 (m, 2H), 3.94–3.79 (m, 1H), 1.50 (s, 3H), 1.36; $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 209.1, 166.3, 153.9, 141.9, 132.3, 131.0, 129.2, 126.7, 87.4, 80.0, 75.8, 61.1, 49.1, 28.0, 14.2; MS (CI), m/z (%) 318 ($\text{M}^+ + 1$, 100).

Ethyl 2-((N-(Buta-2,3-dien-1-yl)-4-methylphenyl)sulfonamido)benzoate (S11e): 90% yield (3 g, 8.1 mmol); amorphous white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.88–7.80 (m, 1H), 7.52–7.44 (m, 2H), 7.36 (hept, J = 5.3 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.97–6.88 (m, 1H), 5.21 (p, J = 7.0 Hz, 1H), 4.55 (dt, J = 6.6, 2.3 Hz, 2H), 4.38–4.15 (m, 5H), 2.36 (s, 4H), 1.34 (t, J = 7.2 Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 209.6, 166.18, 143.3, 137.7, 136.9, 133.1, 131.8, 131.3, 130.9, 129.4, 128.4, 127.5, 86.6, 75.9, 61.3, 50.9, 21.5, 14.1; MS (CI), m/z (%) 372 ($\text{M}^+ + 1$, 100).

Methyl 2-((N-(Buta-2,3-dien-1-yl)-4-methylphenyl)sulfonamido)-4-methylbenzoate (S11f): 85% yield (2.84 g, 7.65 mmol); amorphous white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.74 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.20 (dd, J = 14.1, 7.9 Hz, 3H), 6.86 (s, 1H), 5.37–5.08 (m, 1H), 4.58 (dt, J = 5.8, 2.4 Hz, 2H), 4.27 (s, 2H), 3.68 (d, J = 1.1 Hz, 3H), 2.39 (s, 3H), 2.30 (s, 3H);

$^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 209.6, 166.3, 143.2, 142.9, 137.9, 137.2, 132.5, 131.4, 129.4, 129.1, 129.1, 127.5, 86.8, 75.9, 51.9, 51.0, 21.5, 21.3; MS (CI), m/z (%) 372 ($\text{M}^+ + 1$, 100).

Methyl 2-((N-(Buta-2,3-dien-1-yl)-4-methylphenyl)sulfonamido)-4-(trifluoromethyl)benzoate (S11h): 70% yield (1.3 g, 3 mmol); brown oil; ^1H NMR (500 MHz, CDCl_3) δ 8.0 (dd, J = 8.2, 1.0 Hz, 1H), 7.6 (ddd, J = 8.2, 1.8, 0.8 Hz, 1H), 7.5–7.5 (m, 2H), 7.3–7.2 (m, 2H), 7.1 (d, J = 1.8 Hz, 1H), 5.2 (ddd, J = 7.4, 6.6, 0.9 Hz, 1H), 4.6 (dt, J = 6.6, 2.3 Hz, 2H), 4.3 (dt, J = 7.4, 2.3 Hz, 3H), 3.9 (s, 4H), 2.4 (s, 4H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.2, 165.7, 144.0, 138.7, 133.7 (q, J = 33.2 Hz), 131.8, 129.8, 128.0 (q, J = 3.6 Hz), 127.6, 125.1 (q, J = 3.7 Hz), 123.1 (q, J = 272.8 Hz), 86.1, 76.2, 52.8, 50.9, 21.6; ^{19}F NMR (282 MHz, CDCl_3) δ -63.0; MS (CI), m/z (%) 426 ($\text{M}^+ + 1$, 100).

Methyl 2-((N-(Buta-2,3-dien-1-yl)-4-methylphenyl)sulfonamido)-5-methoxybenzoate (S11i): 70% yield (0.45 g, 1.16 mmol); brown oil; ^1H NMR (500 MHz, CDCl_3) δ 7.52 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 2.6 Hz, 1H), 7.23 (d, J = 7.9 Hz, 2H), 6.94–6.90 (m, 2H), 5.22 (q, J = 6.9 Hz, 1H), 4.60 (d, J = 6.5 Hz, 2H), 4.34 (s, 1H), 4.21 (s, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 2.41 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 209.8, 166.4, 159.1, 143.2, 137.3, 133.5, 132.8, 130.3, 129.5, 127.6, 117.9, 115.9, 86.8, 75.9, 55.8, 52.4, 51.7, 21.6; MS (CI), m/z (%) 388 ($\text{M}^+ + 1$, 100).

Methyl 5-Bromo-2-((N-(buta-2,3-dien-1-yl)-4-methylphenyl)sulfonamido)benzoate (S11j): 80% yield (2.44 g, 5.6 mmol); amorphous white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.96 (d, J = 2.4 Hz, 1H), 7.50 (dd, J = 11.0, 8.3 Hz, 3H), 7.22 (d, J = 8.0 Hz, 2H), 6.85 (d, J = 8.5 Hz, 1H), 5.19 (p, J = 7.0 Hz, 1H), 4.58 (dd, J = 6.6, 2.4 Hz, 2H), 4.25 (dd, J = 7.4, 2.4 Hz, 2H), 3.75 (s, 3H), 2.38 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 209.8, 165.1, 143.6, 136.9, 136.6, 135.0, 134.3, 134.2, 132.79, 129.6, 127.5, 122.3, 86.4, 76.1, 52.5, 50.9, 21.5; MS (CI), m/z (%) 437 ($\text{M}^+ + 1$, 100).

Methyl 2-((N-(Buta-2,3-dien-1-yl)-4-methylphenyl)sulfonamido)-4,5-dimethoxybenzoate (S11n): 56% yield (0.46 g, 1.1 mmol); brown foam; ^1H NMR (500 MHz, CDCl_3) δ 7.55 (d, J = 8.3 Hz, 2H), 7.37 (s, 1H), 7.31–7.18 (m, 3H), 6.52 (s, 1H), 5.26 (t, J = 6.9 Hz, 1H), 4.61 (s, 2H), 4.40 (s, 1H), 4.15 (s, 1H), 3.92 (s, 4H), 3.75 (s, 4H), 3.66 (s, 3H), 2.40 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 209.8, 165.9, 151.5, 148.5, 143.2, 137.5, 132.0, 129.4, 127.7, 124.0, 115.0, 113.4, 87.0, 76.0, 56.2, 56.2, 52.1, 51.4, 21.6; MS (CI), m/z (%) 418 ($\text{M}^+ + 1$, 100).

See the general procedure for the ester reduction of alkynes.

N-(Buta-2,3-dien-1-yl)-N-(2-(hydroxymethyl)phenyl)-4-methylbenzenesulfonamide (3a): 94% yield (2.5 g, 7.6 mmol); amorphous white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.63–7.50 (m, 3H), 7.39–7.24 (m, 3H), 7.14 (td, J = 7.7, 1.7 Hz, 1H), 6.46 (dd, J = 8.0, 1.3 Hz, 1H), 5.10–4.93 (m, 2H), 4.66–4.38 (m, 4H), 3.84 (dd, J = 13.8, 8.3 Hz, 1H), 3.09–2.97 (m, 1H), 2.45 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 209.9, 144.0, 142.4, 136.9, 134.8, 131.0, 129.6, 129.1, 128.3, 128.1, 127.7, 85.3, 76.1, 61.2, 51.4, 21.6; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{18}\text{H}_{18}\text{NO}_2\text{S}$ [$\text{M} - \text{H}_2\text{O}$] $^+$: 312.1053, found 312.1059.

tert-Butyl Buta-2,3-dien-1-yl(2-(hydroxymethyl)phenyl)carbamate (S12d): 88% yield; colorless oil; ^1H NMR (300 MHz, $\text{DMSO}-d_6$, 80 °C) δ 7.52 (d, J = 7.1 Hz, 1H), 7.34–7.17 (m, 2H), 7.12 (dd, J = 7.4, 1.7 Hz, 1H), 5.26 (p, J = 6.6 Hz, 1H), 4.90–4.69 (m, 3H), 4.45 (d, J = 5.3 Hz, 2H), 4.06 (bs, 2H), 1.35 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, $\text{DMSO}-d_6$, 80 °C) δ 208.2, 153.2, 139.4, 139.0, 127.5, 127.1, 126.6, 126.5, 86.6, 78.9, 75.7, 58.7, 48.3, 27.5; MS (CI), m/z (%) 276 ($\text{M}^+ - [\text{OH}]$, 100).

N-(Buta-2,3-dien-1-yl)-N-(2-(hydroxymethyl)-5-methylphenyl)-4-methylbenzenesulfonamide (S12f): 90% yield (2.37 g, 6.9 mmol); amorphous white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.56 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 7.9 Hz, 2H), 7.16 (d, J = 7.8 Hz, 1H), 6.24 (s, 1H), 5.09–4.97 (m, 1H), 4.93 (d, J = 11.9 Hz, 1H), 4.61 (d, J = 7.1 Hz, 1H), 4.57–4.37 (m, 3H), 3.88–3.73 (m, 1H), 2.46 (s, 3H), 2.16 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 209.9, 144.1, 139.2, 138.3, 136.9, 134.8, 130.9, 129.9, 129.5, 128.3, 128.2, 85.5, 76.2, 61.1, 51.4, 21.7, 20.9; MS (CI), m/z (%) 326 ($\text{M}^+ - [\text{OH}]$, 100).

N-(Buta-2,3-dien-1-yl)-*N*-(2-(hydroxymethyl)-5-(trifluoromethyl)phenyl)-4-methylbenzenesulfonamide (**S12h**): 64% yield (0.7 g, 1.86 mmol); amorphous yellow solid; ^1H NMR (500 MHz, CDCl_3) δ 7.8 (d, $J = 8.0$ Hz, 1H), 7.6 (d, $J = 8.1$ Hz, 1H), 7.5 (dd, $J = 8.2, 1.7$ Hz, 2H), 7.3 (d, $J = 7.8$ Hz, 2H), 6.6 (s, 1H), 5.1–5.0 (m, 2H), 4.7–4.6 (m, 2H), 4.5 (q, $J = 10.1$ Hz, 2H), 3.8 (dd, $J = 13.6, 8.5$ Hz, 1H), 2.5 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.5, 146.8, 144.8, 137.5, 134.0, 130.4 (q, $J = 33.0$ Hz), 129.9, 128.2, 125.8 (q, $J = 3.7$ Hz), 125.0 (q, $J = 3.7$ Hz), 123.4 (t, $J = 272.3$ Hz), 85.0, 76.4, 61.0, 51.4, 21.7; MS (CI), m/z (%) 380 $\text{M}^+ - [\text{OH}]$, 100).

N-(Buta-2,3-dien-1-yl)-*N*-(2-(hydroxymethyl)-4-methoxyphenyl)-4-methylbenzenesulfonamide (**S12i**): 54% yield (0.23 g, 0.663 mmol), brown oil; ^1H NMR (500 MHz, CDCl_3) δ 7.6–7.5 (m, 2H), 7.3–7.3 (m, 2H), 7.1 (d, $J = 3.0$ Hz, 1H), 6.6 (dd, $J = 8.8, 3.0$ Hz, 1H), 6.4 (d, $J = 8.8$ Hz, 1H), 5.1–5.0 (m, 1H), 4.9 (d, $J = 12.2$ Hz, 1H), 4.6 (dddd, $J = 11.2, 6.6, 2.9, 1.6$ Hz, 1H), 4.6–4.4 (m, 3H), 3.8 (s, 4H), 3.0 (s, 1H), 2.4 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.0, 159.8, 144.0, 143.9, 135.1, 129.7, 129.4, 128.9, 128.2, 115.0, 114.6, 85.5, 76.2, 61.6, 55.6, 51.7, 21.7; MS (CI), m/z (%) 342 ($\text{M}^+ - [\text{OH}]$, 100).

N-(4-Bromo-2-(hydroxymethyl)phenyl)-*N*-(buta-2,3-dien-1-yl)-4-methylbenzenesulfonamide (**S12j**): 90% yield (2 g, 5 mmol); amorphous white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.79 (d, $J = 2.5$ Hz, 1H), 7.56 (d, $J = 8.1$ Hz, 2H), 7.39–7.17 (m, 3H), 6.33 (d, $J = 8.5$ Hz, 1H), 5.09–4.91 (m, 2H), 4.70–4.35 (m, 5H), 3.88–3.75 (m, 1H), 2.48 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.0, 144.7, 144.4, 135.8, 134.4, 133.6, 131.2, 129.8, 129.2, 128.0, 123.0, 85.2, 76.41, 60.8, 51.3, 21.7; MS (CI), m/z (%) 391 ($\text{M}^+ - [\text{OH}]$, 100).

N-(Buta-2,3-dien-1-yl)-*N*-(2-(hydroxymethyl)-4,5-dimethoxyphenyl)-4-methylbenzenesulfonamide (**S12n**): 57% yield (0.24 g, 0.61 mmol), amorphous white solid; ^1H NMR (500 MHz, CDCl_3) δ 7.6–7.5 (m, 2H), 7.3 (d, $J = 7.9$ Hz, 2H), 7.0 (s, 1H), 5.8 (s, 1H), 5.0 (dt, $J = 7.9, 6.6$ Hz, 1H), 4.9 (d, $J = 11.9$ Hz, 1H), 4.7–4.6 (m, 1H), 4.5 (ddt, $J = 9.4, 6.5, 2.3$ Hz, 1H), 4.5 (ddt, $J = 13.5, 5.9, 2.8$ Hz, 1H), 4.4 (d, $J = 12.0$ Hz, 1H), 3.9 (s, 3H), 3.8 (ddt, $J = 13.7, 8.2, 1.7$ Hz, 1H), 3.5 (s, 3H), 2.4 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.1, 149.4, 148.4, 144.2, 135.4, 135.1, 129.7, 128.9, 128.4, 112.9, 110.5, 85.6, 76.3, 61.2, 56.1, 55.8, 51.6, 21.7; MS (CI), m/z (%) 382 ($\text{M}^+ - [\text{OH}]$, 100).

See the general procedure for the oxidation and reductive amination of alkynes.

tert-Butyl Buta-2,3-dien-1-yl(2-(((4-methoxyphenyl)amino)methyl)phenyl)carbamate (**3d**): 70% yield (1.8 g, 4.8 mmol); yellow oil; ^1H NMR (300 MHz, $\text{DMSO}-d_6$, 80 °C) δ 7.45–7.36 (m, 1H), 7.30–7.14 (m, 3H), 6.68 (d, $J = 8.9$ Hz, 2H), 6.50 (d, $J = 8.9$ Hz, 2H), 5.46 (bs, 1H), 5.33 (p, $J = 6.6$ Hz, 1H), 4.87–4.76 (m, 2H), 4.25 (bs, 1H), 4.15 (s, 2H), 3.97 (bs, 1H), 3.64 (s, 3H), 1.40 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, $\text{DMSO}-d_6$, 80 °C) δ 208.2, 153.2, 150.8, 142.6, 140.0, 137.3, 127.8, 127.3, 126.7, 114.5, 113.0, 86.7, 79.2, 75.9, 55.2, 48.4, 43.4, 27.6; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 381.2173, found 381.2176.

N-(Buta-2,3-dien-1-yl)-*N*-(2-(((4-methoxyphenyl)amino)methyl)phenyl)-4-methylbenzenesulfonamide (**3e**): 70% yield (1.5 g, 3.5 mmol); amorphous white solid; ^1H NMR (500 MHz, CDCl_3) δ 7.62–7.57 (m, 2H), 7.53 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.28 (dd, $J = 10.4, 7.2$ Hz, 3H), 7.12 (td, $J = 7.7, 1.6$ Hz, 1H), 6.80–6.74 (m, 2H), 6.64–6.56 (m, 3H), 5.12 (p, $J = 6.9$ Hz, 1H), 4.70–4.32 (m, 5H), 3.90 (dd, $J = 13.7, 8.4$ Hz, 1H), 3.74 (s, 3H), 2.45 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.0, 152.1, 143.8, 142.6, 141.3, 137.3, 135.5, 129.7, 129.6, 129.3, 128.8, 128.2, 127.9, 127.4, 114.9, 114.3, 85.6, 76.0, 55.8, 51.4, 45.3, 21.6; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$: 435.1737, found 435.1738.

N-(Buta-2,3-dien-1-yl)-*N*-(2-(((4-methoxyphenyl)amino)methyl)-5-methylphenyl)-4-methylbenzenesulfonamide (**3f**): 80% yield (716 mg, 1.6 mmol), amorphous white solid; ^1H NMR (300 MHz, CDCl_3) δ 7.60 (d, $J = 7.9$ Hz, 2H), 7.39 (d, $J = 7.8$ Hz, 1H), 7.29 (d, $J = 8.0$ Hz, 2H), 7.09 (d, $J = 7.8$ Hz, 1H), 6.81 (d, $J = 9$ Hz, 2H), 6.62 (d, $J = 9$ Hz, 2H), 6.41 (s, 1H), 5.11 (p, $J = 6.9$ Hz, 1H), 4.69–4.48 (m, 2H), 4.37 (dd, $J = 16.7, 6.7$ Hz, 3H), 3.88 (dd, $J = 13.6, 8.5$ Hz,

1H), 3.74 (s, 3H), 2.45 (s, 3H), 2.18 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.0, 152.2, 143.9, 142.6, 137.9, 137.4, 137.3, 135.6, 129.7, 129.5, 129.4, 128.9, 128.3, 114.9, 114.5, 85.8, 76.1, 55.9, 51.4, 45.2, 21.7, 20.9; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 449.1893, found 449.1896.

N-(Buta-2,3-dien-1-yl)-*N*-(2-(((4-methoxyphenyl)amino)methyl)-5-(trifluoromethyl)phenyl)-4-methylbenzenesulfonamide (**3h**): 73% yield, (0.7 g, 1.4 mmol), brown oil; ^1H NMR (500 MHz, CDCl_3) δ 7.7 (d, $J = 8.0$ Hz, 1H), 7.6–7.5 (m, 3H), 7.3 (d, $J = 8.0$ Hz, 2H), 6.8 (d, $J = 8.6$ Hz, 2H), 6.7 (s, 1H), 6.6 (d, $J = 8.6$ Hz, 2H), 5.2–5.1 (m, 1H), 4.7 (d, $J = 16.3$ Hz, 1H), 4.6 (t, $J = 8.8$ Hz, 1H), 4.6–4.4 (m, 3H), 3.9–3.8 (m, 1H), 3.7 (s, 3H), 2.5 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.5, 152.4, 146.3, 144.6, 142.1, 138.0, 134.5, 129.9, 129.6, 129.6 (q, $J = 32.9$ Hz), 125.5 (q, $J = 3.7$ Hz), 125.2 (q, $J = 3.7$ Hz), 123.6 (q, $J = 272.2$ Hz), 114.4, 85.2, 76.3, 55.9, 51.4, 45.4, 21.7; ^{19}F NMR (282 MHz, CDCl_3) δ -62.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{26}\text{F}_3\text{N}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 503.1649, found 503.1639.

N-(Buta-2,3-dien-1-yl)-*N*-(4-methoxy-2-(((4-methoxyphenyl)amino)methyl)phenyl)-4-methylbenzenesulfonamide (**3i**): 50% yield, (0.26 g, 0.56 mmol), brown oil; ^1H NMR (500 MHz, CDCl_3) δ 7.7–7.5 (m, 2H), 7.3 (dt, $J = 10.8, 5.3$ Hz, 2H), 7.1 (d, $J = 3.1$ Hz, 1H), 6.8–6.7 (m, 2H), 6.7–6.6 (m, 3H), 6.6–6.5 (m, 1H), 5.2–5.0 (m, 1H), 4.7–4.5 (m, 3H), 4.5–4.3 (m, 2H), 4.0–3.8 (m, 1H), 3.7 (d, $J = 2.7$ Hz, 6H), 2.5–2.4 (m, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.0, 159.6, 152.2, 143.8, 142.8, 142.6, 135.6, 129.7, 129.6, 129.3, 128.1, 114.9, 114.5, 114.0, 113.0, 85.8, 77.4, 76.0, 55.8, 55.4, 51.5, 45.6, 21.6; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_4\text{S}$ [$\text{M} + \text{H}$] $^+$ 465.1843, found 465.1840.

N-(4-Bromo-2-(((4-methoxyphenyl)amino)methyl)phenyl)-*N*-(buta-2,3-dien-1-yl)-4-methylbenzenesulfonamide (**3j**): 65% yield (1.28 g, 2.5 mmol), amorphous white solid; ^1H NMR δ 7.7 (d, $J = 2.4$ Hz, 1H), 7.6 (d, $J = 8.3$ Hz, 2H), 7.4–7.2 (m, 3H), 6.75 (d, $J = 8.9, 2\text{H}$), 6.6 (d, $J = 8.9, 2\text{H}$), 6.4 (d, $J = 8.4$ Hz, 1H), 5.1 (q, $J = 7.0$ Hz, 1H), 4.7–4.5 (m, 3H), 4.4 (d, $J = 15.6$ Hz, 2H), 3.8 (dd, $J = 9.3, 4.4$ Hz, 1H), 3.7 (s, 3H), 2.5 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.2, 152.4, 144.2, 144.0, 132.3, 130.6, 129.8, 129.6, 128.2, 115.0, 114.5, 85.9, 76.4, 55.9, 51.4, 45.4, 21.7; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{BrN}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 513.0842, found 513.0851.

N-(Buta-2,3-dien-1-yl)-*N*-(4,5-dimethoxy-2-(((4-methoxyphenyl)amino)methyl)phenyl)-4-methylbenzenesulfonamide (**3n**): 64% yield (0.18 g, 0.36 mmol), amorphous white solid; ^1H NMR (500 MHz, CDCl_3) δ 7.6 (dt, $J = 8.2, 2.0$ Hz, 2H), 7.3–7.2 (m, 2H), 7.1–7.0 (m, 1H), 6.8 (dt, $J = 8.8, 2.0$ Hz, 2H), 6.6 (dq, $J = 6.7, 2.1$ Hz, 2H), 6.1–5.9 (m, 1H), 5.2–5.0 (m, 1H), 4.7–4.5 (m, 2H), 4.5–4.3 (m, 3H), 3.9 (dd, $J = 13.7, 8.6$ Hz, 1H), 3.8 (t, $J = 1.9$ Hz, 3H), 3.8–3.7 (m, 3H), 3.6–3.5 (m, 3H), 2.4 (d, $J = 2.6$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 210.0, 152.3, 149.2, 147.7, 143.9, 142.7, 135.7, 133.8, 129.5, 129.1, 128.3, 114.9, 114.8, 111.7, 111.2, 85.8, 76.1, 55.9, 55.8, 55.7, 51.5, 45.4, 21.6; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{27}\text{H}_{31}\text{N}_2\text{O}_5\text{S}$ [$\text{M} + \text{H}$] $^+$ 495.1948, found 495.1951.

Preparation of Allenes 3: General Procedure. Tosylamides **S13** were synthesized according to literature.⁴⁴

***N*-Alkylation.** A round-bottomed flask equipped with a stirring magnetic bar was flamed-dried under a vacuum and backfilled with argon. Then, it was charged with K_2CO_3 (2 equiv), and the corresponding tosylamide **S13** was put under a vacuum and backfilled with argon three times. Then DMF (0.25 M) was added, and the mixture was stirred for 30 min at rt. Afterward, a propargyl bromide derivative (1.5 equiv) was added, and the reaction was warmed to 80 °C in an oil bath for 16 h. The reaction was quenched with a saturated solution of NH_4Cl (aq) and extracted with EtOAc. The aqueous layer was extracted with EtOAc, and the combination of organic layers was washed with a saturated solution of NH_4Cl (aq) (3 \times 100 mL), dried over Na_2SO_4 , and concentrated in vacuo. The residue was then purified by silica gel column chromatography with hexanes/EtOAc (7:3) as the eluent to give the propargylated products **S14**.

N-(5-Chloro-2-(hydroxymethyl)phenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (**S14g**): 60% yield (1 g, 3 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.67–7.53 (m, 3H), 7.31 (s, 2H), 7.11 (dd, $J = 8.5, 2.5$ Hz, 1H), 6.58 (d, $J = 8.5$ Hz, 1H), 4.89 (s, 1H), 4.60

(s, 1H), 4.36 (d, $J = 2.5$ Hz, 2H), 2.86 (d, $J = 7.7$ Hz, 1H), 2.45 (s, 3H), 2.17 (t, $J = 2.5$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 144.6, 144.4, 135.6, 135.3, 134.8, 130.8, 129.8, 129.6, 128.5, 128.4, 128.3, 77.2, 74.5, 60.9, 41.9, 21.7; MS (CI), m/z (%) 332 ($\text{M}^+ - [\text{OH}]$, 100).

N-(4-Chloro-2-(hydroxymethyl)phenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (**S14k**): 60% yield (1 g, 2.8 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.66–7.50 (m, 3H), 7.34 (t, $J = 8.8$ Hz, 3H), 6.61 (t, $J = 1.7$ Hz, 1H), 4.96–4.48 (m, 2H), 4.40–4.29 (m, 2H), 2.91 (s, 1H), 2.46 (s, 3H), 2.24–2.14 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, $\text{DMSO}-d_6$) δ 144.8, 141.1, 137.9, 134.5, 133.4, 131.9, 130.0, 129.9, 129.8, 129.6, 128.5, 128.3, 77.0, 74.6, 60.7, 41.9, 21.7; MS (CI), m/z (%) 332 ($\text{M}^+ - [\text{OH}]$, 100).

N-(3-Fluoro-2-(hydroxymethyl)phenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (**S14l**): 53% yield (600 mg, 1.8 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.59 (d, $J = 8.1$ Hz, 2H), 7.38–7.24 (m, 3H), 7.22–7.09 (m, 2H), 6.53–6.44 (m, 1H), 4.82 (s, 2H), 4.40 (d, $J = 2.5$ Hz, 2H), 3.07 (t, $J = 6.9$ Hz, 1H), 2.46 (s, 3H), 2.18 (t, $J = 2.5$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 164.12, 160.8, 144.6, 138.9, 134.7, 129.7, 129.3 (d, $J = 9.8$ Hz), 128.5, 124.2, 124.1, 117.2, 116.9, 77.1, 74.5, 54.8, 42.3, 21.8; ^{19}F NMR (282 MHz, CDCl_3) δ -113.1; MS (CI), m/z (%) 316 ($\text{M}^+ - [\text{OH}]$, 100).

N-(2-(Hydroxymethyl)-3-methylphenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (**S14m**): 53% yield (600 mg, 1.82 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.57 (dd, $J = 8.3, 1.5$ Hz, 2H), 7.35–7.18 (m, 3H), 7.02 (t, $J = 7.8$ Hz, 1H), 6.43 (d, $J = 7.9$ Hz, 1H), 4.98 (d, $J = 11.6$ Hz, 1H), 4.59 (t, $J = 11.3$ Hz, 1H), 4.38 (t, $J = 1.9$ Hz, 2H), 2.99 (dd, $J = 10.8, 3.1$ Hz, 1H), 2.52 (s, 3H), 2.43 (d, $J = 3.6$ Hz, 3H), 2.15 (q, $J = 2.1$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 144.3, 140.7, 140.5, 137.5, 135.0, 131.6, 129.6, 128.5, 128.2, 125.6, 74.2, 57.9, 42.3, 21.7, 19.6; MS (CI), m/z (%) 312 ($\text{M}^+ - [\text{OH}]$, 100).

See the general procedure for homologation of alkynes to allenes.

N-(Buta-2,3-dien-1-yl)-*N*-(5-chloro-2-(hydroxymethyl)phenyl)-4-methylbenzenesulfonamide (**S15g**): 54% yield (450 mg, 1.24 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.55 (dd, $J = 8.3, 1.8$ Hz, 3H), 7.34 (d, $J = 8.0$ Hz, 3H), 6.43 (t, $J = 1.6$ Hz, 1H), 5.10–4.88 (m, 2H), 4.72–4.33 (m, 4H), 3.79 (d, $J = 10.8$ Hz, 1H), 2.87 (t, $J = 6.5$ Hz, 1H), 2.47 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.3, 144.6, 141.3, 138.2, 134.4, 133.4, 132.1, 129.9, 129.5, 128.2, 128.0, 85.2, 76.5, 60.8, 51.4, 21.7; MS (CI), m/z (%) 346 ($\text{M}^+ - [\text{OH}]$, 100).

N-(Buta-2,3-dien-1-yl)-*N*-(4-chloro-2-(hydroxymethyl)phenyl)-4-methylbenzenesulfonamide (**S15k**): 72% yield (750 mg, 2 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.61 (d, $J = 2.6$ Hz, 1H), 7.54 (d, $J = 8.1$ Hz, 2H), 7.31 (d, $J = 7.9$ Hz, 2H), 7.10 (dd, $J = 8.5, 2.5$ Hz, 1H), 6.40 (d, $J = 8.5$ Hz, 1H), 5.09–4.82 (m, 2H), 4.70–4.36 (m, 4H), 3.87–3.75 (m, 1H), 2.86 (s, 1H), 2.46 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.2, 144.6, 144.4, 135.5, 135.0, 134.7, 130.9, 129.9, 129.1, 128.4, 128.2, 85.3, 76.4, 61.0, 51.5, 21.7; MS (CI), m/z (%) 346 ($\text{M}^+ - [\text{OH}]$, 100).

N-(Buta-2,3-dien-1-yl)-*N*-(3-fluoro-2-(hydroxymethyl)phenyl)-4-methylbenzenesulfonamide (**S15l**): 50% yield (310 mg, 0.9 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.55 (d, $J = 8.0$ Hz, 2H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.13 (qd, $J = 8.3, 6.3$ Hz, 2H), 6.30 (dd, $J = 7.0, 2.2$ Hz, 1H), 5.04 (q, $J = 7.0$ Hz, 1H), 4.94–4.39 (m, 5H), 3.82 (t, $J = 10.9$ Hz, 1H), 3.25–3.13 (m, 1H), 2.46 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.0, 164.1, 160.8, 144.3, 134.4, 129.7, 129.0 (d, $J = 9.9$ Hz), 128.1, 123.5 (d, $J = 3.4$ Hz), 116.5, 116.2, 85.2, 76.3, 54.8, 54.8, 51.5, 21.6; ^{19}F NMR (282 MHz, CDCl_3) δ -113.5; MS (CI), m/z (%) 330 ($\text{M}^+ - [\text{OH}]$, 100).

N-(Buta-2,3-dien-1-yl)-*N*-(2-(hydroxymethyl)-3-methylphenyl)-4-methylbenzenesulfonamide (**S15m**): 70% yield (435 mg, 1.27 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.54 (d, $J = 7.9$ Hz, 2H), 7.37–7.26 (m, 2H), 7.19 (d, $J = 7.5$ Hz, 1H), 7.02 (t, $J = 7.8$ Hz, 1H), 6.27 (d, $J = 8.0$ Hz, 1H), 5.15–4.98 (m, 2H), 4.72–4.36 (m, 4H), 3.89–3.75 (m, 1H), 3.09 (dd, $J = 11.0, 2.8$ Hz, 1H), 2.54 (s, 3H), 2.45 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.0, 144.1, 140.6, 137.6, 134.9, 131.1, 129.7, 128.3, 128.0, 125.1, 85.6, 76.2, 58.0, 51.6, 21.7, 19.6; MS (CI), m/z (%) 326 ($\text{M}^+ - [\text{OH}]$, 100).

See the general procedure for oxidation and reductive amination.

N-(Buta-2,3-dien-1-yl)-*N*-(5-chloro-2-(((4-methoxyphenyl)amino)methyl)phenyl)-4-methylbenzenesulfonamide (**3g**): 57% yield (330 mg, 0.71 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.5 (d, $J = 7.9$ Hz, 2H), 7.4 (d, $J = 8.3$ Hz, 1H), 7.2 (d, $J = 8.0$ Hz, 2H), 7.1 (dd, $J = 8.4, 2.2$ Hz, 1H), 6.7 (d, $J = 9$ Hz, 2H), 6.5–6.4 (m, 3H), 5.0 (p, $J = 7.0$ Hz, 1H), 4.6–4.2 (m, 5H), 3.8–3.7 (m, 1H), 3.6 (s, 3H), 2.4 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.2, 152.3, 144.3, 142.3, 140.3, 138.5, 134.9, 132.3, 130.3, 129.8, 129.0, 128.3, 128.2, 115.0, 114.4, 85.4, 76.3, 55.9, 51.3, 45.0, 21.7; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{ClN}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 469.1347, found 469.1351.

N-(Buta-2,3-dien-1-yl)-*N*-(4-chloro-2-(((4-methoxyphenyl)amino)methyl)phenyl)-4-methylbenzenesulfonamide (**3k**): 56% yield (530 mg, 1.13 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.62–7.50 (m, 3H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.09 (dd, $J = 8.5, 2.6$ Hz, 1H), 6.77 (d, $J = 8.7$ Hz, 2H), 6.58 (d, $J = 8.7$ Hz, 2H), 6.51 (d, $J = 8.5$ Hz, 1H), 5.11 (p, $J = 7.0$ Hz, 1H), 4.72–4.48 (m, 3H), 4.41 (d, $J = 15.5$ Hz, 2H), 3.83 (dd, $J = 13.9, 8.3$ Hz, 1H), 3.74 (s, 3H), 2.45 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.2, 152.4, 144.2, 143.8, 142.3, 135.9, 135.3, 134.9, 129.8, 129.4, 129.3, 128.2, 127.5, 115.0, 11447.5, 85.5, 76.3, 55.9, 51.4, 45.4, 21.7; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{ClN}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 469.1347, found 469.1348.

N-(Buta-2,3-dien-1-yl)-*N*-(3-fluoro-2-(((4-methoxyphenyl)amino)methyl)phenyl)-4-methylbenzenesulfonamide (**3l**): 52% yield (210 mg, 0.47 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.59 (d, $J = 8.0$ Hz, 2H), 7.29 (d, $J = 7.9$ Hz, 2H), 7.21–7.04 (m, 2H), 6.81 (d, $J = 9.0$ Hz, 2H), 6.77–6.67 (m, 2H), 6.47 (d, $J = 7.7$ Hz, 1H), 5.03 (p, $J = 6.9$ Hz, 1H), 4.67–4.45 (m, 3H), 4.41–4.21 (m, 2H), 3.97–3.84 (m, 1H), 3.76 (s, 3H), 2.45 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 210.0, 162.3 (d, $J = 248.7$ Hz), 152.6, 144.2, 142.8, 139.8 (d, $J = 6.3$ Hz), 135.2, 129.7, 128.9, 128.6 (d, $J = 9.9$ Hz), 128.4, 128.2, 124.5 (d, $J = 3.4$ Hz), 116.2 (d, $J = 22.8$ Hz), 115.2, 114.9, 85.5, 76.2, 55.9, 51.7, 39.8, 21.7; ^{19}F NMR (282 MHz, CDCl_3) δ -113.1 (t, $J = 7.8$ Hz); HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{FN}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 453.1643, found 453.1645.

N-(Buta-2,3-dien-1-yl)-*N*-(2-(((4-methoxyphenyl)amino)methyl)-3-methylphenyl)-4-methylbenzenesulfonamide (**3m**): 58% yield (330 mg, 0.74 mmol); ^1H NMR (300 MHz, CDCl_3) δ 7.60 (d, $J = 8.1$ Hz, 2H), 7.27 (d, $J = 8.0$ Hz, 2H), 7.20 (d, $J = 7.6$ Hz, 1H), 7.08 (t, $J = 7.7$ Hz, 1H), 6.82 (d, $J = 8.9$ Hz, 2H), 6.70 (d, $J = 8.9$ Hz, 2H), 6.48 (d, $J = 7.8$ Hz, 1H), 5.05 (dq, $J = 8.0, 6.6$ Hz, 1H), 4.68–4.46 (m, 2H), 4.46–4.20 (m, 3H), 3.90 (ddt, $J = 13.8, 8.2, 1.8$ Hz, 1H), 3.77 (s, 3H), 2.47 (s, 3H), 2.44 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 209.8, 152.3, 143.8, 143.4, 140.2, 138.8, 138.2, 135.6, 131.0, 129.6, 128.2, 127.6, 125.9, 114.9, 114.6, 85.6, 76.0, 55.9, 51.6, 42.6, 21.6, 19.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_3\text{S}$ [$\text{M} + \text{H}$] $^+$: 449.1893, found 449.1896.

General Procedure for the Asymmetric Cyclization of Allenes 3.

A 5 mL sealed tube equipped with a stirring magnetic bar was flamed-dried under a vacuum, cooled to rt, and backfilled with argon. Then it was charged with $[\text{Rh}(\text{cod})\text{Cl}]_2$ (3 mg, 6 μmol , 0.04 equiv), PPTS (4 mg, 15 μmol , 0.1 equiv) or $\text{ClCH}_2\text{CO}_2\text{H}$ (1.4 mg, 15 μmol , 0.1 equiv), and (*R*)-DTBM-Garphos (19 mg, 15 μmol , 0.1 equiv). Afterward, it was put in a vacuum and backfilled with argon for three times. Then 0.4 mL of DCE was added, and the mixture was stirred for 10 min at rt. Finally, the allene **3** (0.15 mmol, 1 equiv) was added under a flow of argon, and the mixture was stirred at 50 °C in an oil bath for 24 h. After the mixture was cooled at rt and the solvent was stripped off, the resulting residue was purified by silica gel column chromatography with hexanes/EtOAc (9:1) as the eluent to give the desired seven-membered heterocycle **2**.

1-Tosyl-3-vinyl-1,2,3,5-tetrahydrobenzo[e][1,4]oxazepine (2a): used the general procedure with PPTS as Bronsted acid, 90%, 56% ee, $[\alpha]_{\text{D}}^{25} -7.54$ (c 1, CHCl_3). SFC conditions: 30% MeOH, Phenomenex Amylose 1 at 40 °C, ($\text{CO}_2/\text{MeOH} = 70:30$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 5.98, minor = 6.96. See other spectroscopic data of **2a** in the racemic cyclization of alkyne **1a**.

(R)-4-(4-Methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine (2e): PPTS as Bronsted acid, 70% yield,

amorphous off-white solid, 90% ee, $[\alpha]_{\text{D}}^{25} -22.4$ (c 0.5, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.78 (d, $J = 8.1$ Hz, 1H), 7.22–7.03 (m, 5H), 6.64 (d, $J = 8$ Hz, 2H), 6.51 (d, $J = 9$ Hz, 2H), 6.25 (d, $J = 9$ Hz, 2H), 5.75 (ddd, $J = 17.3, 10.6, 3.9$ Hz, 1H), 5.16 (dd, $J = 28.1, 13.9$ Hz, 2H), 4.57–4.36 (m, 3H), 4.04 (d, $J = 17.2$ Hz, 1H), 3.65 (s, 3H), 3.47 (q, $J = 13.4, 12.7$ Hz, 1H), 2.08 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 152.1, 144.0, 143.0, 139.5, 136.2, 133.6, 129.9, 129.1, 128.5, 127.7, 126.8, 126.5, 126.4, 117.2, 114.8, 114.4, 60.3, 55.7, 54.3, 51.3, 21.4; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 435.1737, found 435.1738. SFC conditions: 30% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 70:30$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 19.26, minor = 22.02).

(*R*)-4-(4-Methoxyphenyl)-8-methyl-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2f**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 86% yield, amorphous off-white solid, 86% ee, $[\alpha]_{\text{D}}^{25} -70.17$ (c 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 7.68 (s, 1H), 7.20 (d, $J = 8.3$ Hz, 2H), 7.08–6.91 (m, 2H), 6.72 (d, $J = 8.1$ Hz, 2H), 6.60 (d, $J = 9$ Hz, 2H), 6.30 (d, $J = 9$ Hz, 2H), 5.82 (ddd, $J = 16.9, 10.9, 3.5$ Hz, 1H), 5.31–5.14 (m, 3H), 4.61–4.37 (m, 3H), 4.07 (d, $J = 17.1$ Hz, 1H), 3.73 (d, $J = 2.1$ Hz, 3H), 3.61–3.43 (m, 1H), 2.34 (s, 3H), 2.16 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 152.05, 144.0, 143.0, 139.4, 137.6, 136.2, 133.7, 130.6, 129.1, 128.3, 127.2, 126.9, 126.8, 117.1, 114.9, 114.4, 60.3, 55.7, 54.3, 51.1, 21.5, 21.3; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 449.1893, found 449.1896. SFC conditions: 30% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 70:30$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 33.15, minor = 30.60).

(*R*)-8-Chloro-4-(4-methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2g**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 55% yield, amorphous off-white solid, 92% ee, $[\alpha]_{\text{D}}^{25} -17.20$ (c 1, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.8 (d, $J = 2.2$ Hz, 1H), 7.16 (d, $J = 7.9$ Hz, 1H), 7.07 (dd, $J = 8.2, 2.1$ Hz, 1H), 7.00 (d, $J = 8.1$ Hz, 1H), 6.68 (d, $J = 8.0$ Hz, 2H), 6.58–6.48 (m, 2H), 6.23 (d, $J = 8.5$ Hz, 2H), 5.75 (ddd, $J = 17.2, 10.5, 3.8$ Hz, 1H), 5.27–5.11 (m, 2H), 4.57–4.38 (m, 3H), 4.03 (d, $J = 17.4$ Hz, 1H), 3.66 (s, 4H), 3.52–3.38 (m, 1H), 2.10 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 152.3, 143.9, 143.5, 140.7, 135.4, 133.1, 130.1, 129.5, 129.3, 127.0, 126.4, 126.1, 117.4, 114.9, 114.5, 60.5, 55.8, 54.1, 50.9, 21.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{ClN}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 469.1347, found 469.1348. SFC conditions: 30% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 70:30$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 19.78, minor = 16.24).

(*R*)-4-(4-Methoxyphenyl)-1-tosyl-8-(trifluoromethyl)-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2h**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 99% yield, amorphous off-yellow solid, 90% ee, $[\alpha]_{\text{D}}^{25} -37.40$ (c 1, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 8.1 (s, 1H), 7.4 (d, $J = 7.9$ Hz, 1H), 7.3 (d, $J = 8.0$ Hz, 1H), 7.2 (d, $J = 7.9$ Hz, 2H), 6.7 (d, $J = 8.0$ Hz, 2H), 6.6 (d, $J = 8.5$ Hz, 2H), 6.3 (d, $J = 8.4$ Hz, 2H), 5.8 (ddd, $J = 17.2, 10.3, 3.5$ Hz, 1H), 5.3–5.2 (m, 2H), 4.6 (d, $J = 17.5$ Hz, 1H), 4.6–4.5 (m, 2H), 4.2 (d, $J = 17.5$ Hz, 1H), 3.7 (d, $J = 1.3$ Hz, 3H), 3.5 (s, 1H), 2.2 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 152.4, 143.8, 143.6, 140.2, 137.3, 135.6, 133.3, 129.3, 127.2, 123.8 (q, $J = 272.5$ Hz), 123.0–122.9 (m), 117.4, 115.0, 114.9, 114.6, 60.5, 55.8, 54.0, 51.1, 21.5; ^{19}F NMR (282 MHz, CDCl_3) δ -62.4; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{26}\text{F}_3\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 504.1689, found 504.1683. SFC conditions: 20% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 80:20$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 15.05, minor = 12.15).

(*R*)-7-Methoxy-4-(4-methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2i**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 86% yield, amorphous off-yellow solid, 90% ee, $[\alpha]_{\text{D}}^{25} -66.28$ (c 1, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.8 (d, $J = 8.9$ Hz, 1H), 7.2 (d, $J = 7.9$ Hz, 2H), 6.8–6.7 (m, 3H), 6.7 (d, $J = 3.0$ Hz, 1H), 6.55 (d, $J = 8.5$ Hz, 2H), 6.3 (d, $J = 8.5$ Hz, 2H), 5.8 (ddd, $J = 17.3, 10.6, 4.0$ Hz, 1H), 5.3–5.1 (m, 2H), 4.6–4.4 (m, 3H), 4.0 (d, $J = 17.1$ Hz, 1H), 3.8 (s, 3H), 3.7 (s, 3H), 3.5 (s, 1H), 2.2 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 157.9, 152.3, 144.0, 142.9, 136.4, 135.8, 133.8, 132.4, 129.1, 128.2, 126.7, 117.2, 115.4, 114.3, 113.9, 112.2, 60.3, 55.7, 55.6, 54.5, 51.8, 21.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_4\text{S}$ $[\text{M} + \text{H}]^+$ 465.1843, found 465.1858. SFC

conditions: 20% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 80:20$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 15.71, minor = 16.97).

(*R*)-7-Bromo-4-(4-methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2j**): $\text{ClCH}_2\text{CO}_2\text{H}$ as Brønsted acid, 70% yield, amorphous off-white solid, 88% ee, $[\alpha]_{\text{D}}^{25} -11.69$ (c 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 7.8 (d, $J = 8.7$ Hz, 1H), 7.3 (dd, $J = 8.7, 2.4$ Hz, 1H), 7.3 (d, $J = 2.4$ Hz, 1H), 7.2 (d, $J = 8.0$ Hz, 2H), 6.7 (d, $J = 8.0$ Hz, 2H), 6.60 (d, $J = 9.0$ Hz, 2H), 6.25 (d, $J = 9.0$ Hz, 2H), 5.8 (ddd, $J = 17.2, 10.5, 3.7$ Hz, 1H), 5.3–5.1 (m, 2H), 4.7–4.4 (m, 3H), 4.1 (d, $J = 17.5$ Hz, 1H), 3.74 (s, 3H), 3.5 (dd, $J = 14.8, 10.6$ Hz, 1H), 2.2 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 152.3, 143.7, 143.4, 138.8, 135.8, 133.2, 131.2, 130.6, 130.0, 129.3, 128.0, 126.9, 119.6, 117.43, 114.8, 114.5, 60.2, 55.7, 54.2, 50.9, 21.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{BrN}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 513.0842, found 513.0851. SFC conditions: 30% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 70:30$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 24.37, minor = 21.15).

(*R*)-7-Chloro-4-(4-methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2k**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 72% yield, amorphous off-white solid, 94% ee, $[\alpha]_{\text{D}}^{25} -17.20$ (c 1, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.74 (d, $J = 8.7$ Hz, 1H), 7.18–7.00 (m, 4H), 6.65 (d, $J = 7.9$ Hz, 2H), 6.55 (d, $J = 8.8$ Hz, 2H), 6.23 (d, $J = 8.8$ Hz, 2H), 5.74 (ddd, $J = 17.3, 10.5, 4.0$ Hz, 1H), 5.25–5.07 (m, 2H), 4.55–4.36 (m, 3H), 3.98 (d, $J = 17.4$ Hz, 1H), 3.66 (s, 3H), 3.40 (d, $J = 15.6$ Hz, 1H), 2.09 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 152.4, 143.8, 143.3, 138.3, 135.9, 135.6, 133.3, 131.7, 129.3, 128.3, 127.7, 127.6, 126.9, 117.4, 114.9, 114.5, 60.3, 55.7, 54.3, 51.1, 21.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{ClN}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 469.1347, found 469.1348. SFC conditions: 30% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 70:30$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 20.09, minor = 17.33).

(*R*)-6-Fluoro-4-(4-methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2l**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 60% yield, amorphous off-white foam, 90% ee, $[\alpha]_{\text{D}}^{25} -6.50$ (c 1, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.59 (d, $J = 8.3$ Hz, 1H), 7.23–7.05 (m, 3H), 6.84 (t, $J = 8.8$ Hz, 1H), 6.66 (d, $J = 7.8$ Hz, 2H), 6.55 (d, $J = 8.4$ Hz, 2H), 6.26 (d, $J = 8.4$ Hz, 2H), 5.77 (ddd, $J = 17.3, 10.5, 3.7$ Hz, 1H), 5.27–5.12 (m, 2H), 4.56 (d, $J = 17.8$ Hz, 1H), 4.46 (dd, $J = 10.7, 5.4$ Hz, 2H), 4.29 (d, $J = 17.8$ Hz, 1H), 3.66 (s, 3H), 3.55–3.41 (m, 1H), 2.09 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 159.9 (d, $J = 244.3$ Hz), 152.1, 143.7, 143.2, 141.4 (d, $J = 5.0$ Hz), 135.8, 133.2, 129.1, 127.8 (d, $J = 10.0$ Hz), 126.8, 121.5, 121.4, 117.3, 114.6, 114.4, 112.8 (d, $J = 23.0$ Hz), 60.1, 55.6, 54.10, 42.7, 21.4; ^{19}F NMR (282 MHz, CDCl_3) δ -116.32 (t, $J = 8.3$ Hz); HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{FN}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 453.1643, found 453.1643. SFC conditions: 20% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 80:20$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 19.08, minor = 17.66).

(*R*)-4-(4-Methoxyphenyl)-6-methyl-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2m**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 86% yield, brown oil, 94% ee, $[\alpha]_{\text{D}}^{25} -20.65$ (c 1, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.60 (d, $J = 7.8$ Hz, 1H), 7.18 (s, 2H), 7.03 (t, $J = 7.8$ Hz, 1H), 6.95 (d, $J = 7.5$ Hz, 1H), 6.70 (d, $J = 7.9$ Hz, 2H), 6.58–6.50 (m, 2H), 6.25 (d, $J = 8.6$ Hz, 2H), 5.71 (ddd, $J = 17.2, 10.6, 4.5$ Hz, 1H), 5.21–5.11 (m, 2H), 4.49–4.36 (m, 2H), 4.25 (q, $J = 17.3$ Hz, 2H), 3.66 (s, 3H), 3.36 (dd, $J = 14.7, 10.8$ Hz, 1H), 2.19 (s, 3H), 2.12 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 152.6, 144.7, 142.9, 140.0, 136.5, 136.1, 134.1, 131.7, 129.2, 128.7, 126.9, 124.6, 119.4, 117.4, 116.3, 114.4, 60.4, 55.7, 54.6, 48.5, 21.5, 20.3; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 449.1893, found 449.1896. SFC conditions: 20% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 80:20$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 20.98, minor = 19.36).

(*R*)-7,8-Dimethoxy-4-(4-methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1*H*-benzo[e][1,4]diazepine (**2n**): $\text{ClCH}_2\text{CO}_2\text{H}$ as a Brønsted acid, 78% yield, amorphous off-white foam, 96% ee, $[\alpha]_{\text{D}}^{25} -76.38$ (c 1, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.5–7.4 (m,

1H), 7.2 (d, $J = 7.9$ Hz, 2H), 6.7 (d, $J = 7.9$ Hz, 2H), 6.6–6.5 (m, 3H), 6.3 (d, $J = 8.4$ Hz, 2H), 5.8 (ddd, $J = 17.1, 10.5, 4.1$ Hz, 1H), 5.3–5.1 (m, 2H), 4.5 (d, $J = 17.0$ Hz, 2H), 4.4 (dd, $J = 10.6, 4.8$ Hz, 1H), 4.0 (d, $J = 17.1$ Hz, 1H), 3.9 (d, $J = 2.6$ Hz, 6H), 3.7 (s, 3H), 3.5 (d, $J = 14.6$ Hz, 1H), 2.2 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 152.3, 147.7, 147.2, 144.0, 143.0, 136.2, 133.8, 132.3, 129.2, 126.8, 126.0, 122.2, 117.2, 115.3, 114.3, 110.7, 60.5, 56.2, 56.1, 55.7, 54.6, 51.4, 21.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{27}\text{H}_{31}\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 495.1948, found 495.1958. SFC conditions: 20% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 80:20$, 2 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 11.50, minor = 12.90).

Derivatization of (R)-4-(4-Methoxyphenyl)-1-tosyl-3-vinyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine (2e). (R)-1-Tosyl-3-vinyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-4-ium chloride (4).³¹ A solution of PMP-protected amine 2e (110 mg, 0.25 mmol) in 8.0 mL of MeCN was cooled in an ice bath and treated with a solution of CAN (275 mg, 0.5 mmol, 2.5 equiv) in water (8 mL) dropwise. The reaction allowed to warm to 25 °C and stirred for 3 h. The crude reaction was diluted with water and washed with Et_2O , and the organic layer was discarded. The aqueous layer was basified to pH 10 with a saturated Na_2CO_3 solution and extracted with Et_2O . The combined organic layers were dried with MgSO_4 and treated with a 1 M HCl solution in Et_2O and concentrated to afford the hydrochloride salt of the product as an amorphous white solid: 77 mg, 85% yield, $[\alpha]_{\text{D}}^{25}$ 122.7 (c 0.70, MeOH); ^1H NMR (300 MHz, methanol- d_4) δ 7.77 (d, $J = 7.8$ Hz, 2H), 7.56 (dd, $J = 5.8, 3.2$ Hz, 1H), 7.45 (dd, $J = 8.5, 4.5$ Hz, 4H), 7.31–7.17 (m, 1H), 5.86 (ddd, $J = 17.4, 10.5, 7.0$ Hz, 1H), 5.73–5.54 (m, 2H), 4.51 (dd, $J = 15.7, 2.6$ Hz, 1H), 4.31 (d, $J = 14.1$ Hz, 1H), 4.25–4.15 (m, 1H), 4.09 (d, $J = 14.0$ Hz, 1H), 3.44–3.29 (m, 2H), 2.48 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, methanol- d_4) δ 148.8, 144.4, 141.2, 135.5, 135.3, 134.6, 133.9, 133.7, 132.8, 132.2, 131.1, 126.3, 66.2, 54.8, 52.8, 24.1; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{18}\text{H}_{21}\text{ClN}_2\text{O}_2\text{S}$ $[\text{M} - \text{Cl} + \text{H}]^+$ 329.1324, found 329.1320.

(R)-4-(4-Methoxyphenyl)-3-vinyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine (5).³² To a solution of naphthalene (4 mg, 0.02 mmol, 0.2 equiv) in anhydrous THF (1 mL) in an oven-dried Schlenk flask under a stream of argon were added hexane-rinsed sheets of sodium metal (21.2 mg, 0.885 mmol, 6 equiv). The mixture was then sonicated at rt until a green color persisted when a solution of 2e (62 mg, 0.143 mmol) in THF (4 mL) was added, resulting in a rapid loss of the green color. The turbid yellow reaction mixture was removed from the sonicator and stirred at rt for 15 h. Afterward, the reaction was cooled to 0 °C, and 10 mL of MeOH was slowly added to quench the Na followed by the addition of a saturated solution of NaHCO_3 (only after consumption). The reaction was diluted with Et_2O and washed with NaHCO_3 and H_2O . The organic layer was dried over Na_2SO_4 and concentrated in vacuo. The product was purified by silica gel column chromatography with hexanes/EtOAc (8:2) as the eluent to give the desired product 5: 85% yield (34 mg), colorless oil, $[\alpha]_{\text{D}}^{25}$ –50.1 (c 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 7.16 (d, $J = 7.4$ Hz, 1H), 7.01 (t, $J = 7.6$ Hz, 1H), 6.88–6.55 (m, 5H), 6.50 (d, $J = 7.9$ Hz, 1H), 5.90 (ddd, $J = 17.0, 10.3, 3.9$ Hz, 1H), 5.29 (dd, $J = 25.6, 13.9$ Hz, 2H), 5.01 (d, $J = 17.1$ Hz, 1H), 4.50–4.37 (m, 1H), 4.19 (d, $J = 17.1$ Hz, 1H), 3.9 (bs, 1H), 3.70 (s, 3H), 3.67–3.58 (m, 1H), 3.40 (dd, $J = 14.3, 5.4$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 151.3, 147.8, 145.0, 135.4, 129.4, 127.4, 124.8, 119.0, 116.6, 115.5, 114.7, 113.1, 64.8, 55.8, 50.2, 48.5; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{18}\text{H}_{21}\text{ClN}_2\text{O}_2\text{S}$ $[\text{M} + \text{H}]^+$ 281.1648, found 281.1647.

(R)-1-(1-Tosyl-3-vinyl-1,2,3,5-tetrahydro-4H-benzo[e][1,4]diazepin-4-yl) prop-2-en-1-one (6). To a suspension of 4 (45 mg, 0.123 mmol) and DMAP (1.5 mg, 0.012 mmol, 0.1 equiv) in DCM (0.1 M) cooled in an ice-bath was added Et_3N (60 μL , 0.5 mmol, 4 equiv). After the mixture was stirred for 5 min, acryloyl chloride (20 μL , 0.247 mmol, 2 equiv) was added dropwise. The reaction was allowed to warm to rt and stirred for 2 h. The crude reaction was diluted with H_2O and extracted with DCM. The organic layer was washed with an aqueous solution of 5% HCl, brine, dried over Na_2SO_4 , and concentrated in vacuo. The resulting product was purified by silica gel column chromatography with hexanes/EtOAc (7:3) as the eluent

to give the desired product 6: 65% yield (30 mg), amorphous off-white solid, $[\alpha]_{\text{D}}^{25}$ –8.90 (c 0.7, CHCl_3); ^1H NMR (300 MHz, $\text{DMSO}-d_6$, 80 °C) δ 7.62 (d, $J = 7.9$ Hz, 2H), 7.40–7.09 (m, 6H), 6.54 (dd, $J = 16.7, 10.5$ Hz, 1H), 5.99 (ddd, $J = 16.4, 13.8, 3.5$ Hz, 2H), 5.63 (dd, $J = 10.4, 2.3$ Hz, 1H), 5.24 (dd, $J = 22.5, 14.0$ Hz, 2H), 4.60 (d, $J = 132.9$ Hz, 3H), 4.11–4.00 (m, 2H), 2.35 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, $\text{DMSO}-d_6$, 80 °C) δ 165.4, 143.3, 139.3, 137.1, 133.7, 132.1, 129.5, 129.0, 128.0, 127.2, 127.1, 126.5, 125.7, 124.1, 116.6, 52.0, 44.7, 39.8, 20.6; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 383.1424, found 383.1422.

(R)-10-Tosyl-5,10,11,11a-tetrahydro-3H-benzo[*e*]pyrrolo[1,2-*a*]-[1,4]diazepin-3-one (7).⁴⁵ A flame-dried Schlenk was charged with the Hoveyda–Grubbs second generation catalyst (2.5 mg, 0.004 mmol, 0.1 equiv), and it was put under a vacuum and backfilled with argon. Afterward, a solution of 5 (15 mg, 0.04 mmol, 1 equiv) in dry DCM (1.5 mL) was added, and the reaction was refluxed in an oil bath for 36 h. Then, the reaction crude was purified by silica gel column chromatography with a gradient of hexanes/EtOAc (60:40) to 100% EtOAc as the eluent to give the desired product 7: 87% yield (12 mg), white foam, 88% ee, $[\alpha]_{\text{D}}^{25}$ –8.10 (c 0.5, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.70–7.58 (m, 2H), 7.39 (dd, $J = 7.3, 1.8$ Hz, 1H), 7.32–7.21 (m, 4H), 7.16 (dd, $J = 7.6, 1.6$ Hz, 1H), 6.93 (dd, $J = 6.0, 1.7$ Hz, 1H), 6.19 (dd, $J = 6.0, 1.7$ Hz, 1H), 4.84 (d, $J = 14.9$ Hz, 1H), 4.72 (dd, $J = 14.5, 3.4$ Hz, 1H), 4.67–4.55 (m, 1H), 3.83 (d, $J = 14.9$ Hz, 1H), 2.73 (dd, $J = 14.5, 11.3$ Hz, 1H), 2.44 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 169.1, 144.3, 142.8, 139.8, 138.3, 137.1, 130.2, 130.1, 129.6, 129.5, 129.1, 129.0, 127.3, 64.7, 53.8, 44.0, 21.7; HRMS (MM: ESI-APCI+) m/z calcd for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 355.1111, found 355.1111. SFC conditions: 40% MeOH, Phenomenex Amylose-1 at 40 °C ($\text{CO}_2/\text{MeOH} = 60:40$, 1 mL/min), $\lambda = 210$ nm, t_{R} (min): major = 9.12, minor = 11.06).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.1c01268>.

Optimization procedures, X-ray crystallographic data, chiral HPL, and NMR spectra for all new compounds (PDF)

Accession Codes

CCDC 1983304 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ AUTHOR INFORMATION

Corresponding Author

Carlos Saá – Centro Singular de Investigación en Química Biológica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain; orcid.org/0000-0003-3213-4604; Email: carlos.saa@usc.es

Authors

Álvaro Velasco-Rubio – Centro Singular de Investigación en Química Biológica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

Rodrigo Bernárdez – Centro Singular de Investigación en Química Biológica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de

Santiago de Compostela, 15782 Santiago de Compostela, Spain

Jesús A. Varela – Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain;
orcid.org/0000-0001-8499-4257

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acs.joc.1c01268>

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work received financial support from MINECO (project CTQ2017-87939R and ORFEO-CINQA network RED2018-102387-T), the Xunta de Galicia (project ED431C 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022, ED431G 2019/03), and the European Union (European Regional Development Fund, ERDF). A.V.-R. thanks Xunta de Galicia for a predoctoral fellowship (ED481A-2018/34, 2018-2021).

REFERENCES

- (1) (a) Ouyang, W.; Rao, J.; Li, Y.; Liu, X.; Huo, Y.; Chen, Q.; Li, X. Recent Achievements in the Rhodium-Catalyzed Concise Construction of Medium N-Heterocycles, Azepines and Azocines. *Adv. Synth. Catal.* **2020**, *362*, 5576–5600. (b) Velasco-Rubio, Á.; Varela, J. A.; Saá, C. Recent Advances in Transition-Metal-Catalyzed Oxidative Annulations to Benzazepines and Benzodiazepines. *Adv. Synth. Catal.* **2020**, *362*, 4861–4875.
- (2) (a) Haefely, W.; Kyburz, E.; Gerecke, M.; Moehler, H. Recent advances in the molecular pharmacology of benzodiazepine receptors and antagonists. *Adv. Drug Res.* **1985**, *14*, 165–322. (b) Clayton, T.; Poe, M. M.; Rallapalli, S.; Biawat, P.; Savic, M. M.; Rowlett, J. K.; Gallos, G.; Emala, C. W.; Kaczorowski, C. C.; Stafford, D. C.; Arnold, L. A.; Cook, J. M. A review of the updated pharmacophore for the alpha 5 GABA(A) benzodiazepine receptor model. *Int. J. Med. Chem.* **2020**, 430248–430302. (c) Khan, I.; Anupama; Singh, B. 1,4-benzodiazepine: an overview of biological properties. *Sci. Rev. Chem. Commun.* **2015**, *5*, 13–20. (d) Batlle, E.; Lizano, E.; Viñas, M.; Pujol, M. D. 1,4-Benzodiazepines and New Derivatives: Description, Analysis, and Organic Synthesis. In *Medicinal Chemistry*; IntechOpen, 2018; p 28.
- (3) *Handbook of Psychopharmacology: Biochemical Studies of CNS Receptors*; Iversen, L. L., Iversen, S. D., Snyder, S. H., Eds.; Springer, 1983; Vol. 17, p 436.
- (4) Cai, Q.; Sun, H.; Peng, Y.; Lu, J.; Nikolovska-Coleska, Z.; McEachern, D.; Liu, L.; Qiu, S.; Yang, C.-Y.; Miller, R.; Yi, H.; Zhang, T.; Sun, D.; Kang, S.; Guo, M.; Leopold, L.; Yang, D.; Wang, S. A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment. *J. Med. Chem.* **2011**, *54*, 2714–2726.
- (5) De Lucca, G. V.; Otto, M. J. Synthesis and anti-HIV activity of pyrrolo[1,2-d]-(1,4)-benzodiazepin-6-ones. *Bioorg. Med. Chem. Lett.* **1992**, *2*, 1639–1644.
- (6) (a) Knabe, J.; Bender, S. 1,5-Benzodiazepine, 1. Mitt.: Racemate und Enantiomere von 3,3-Dialkyl-1,5-benzodiazepin-2,4-dionen: Synthese, Konfiguration und enantiomere Reinheit. *Arch. Pharm.* **1993**, *326*, 551–558. (b) Barlind, J. G.; Buckett, L. K.; Crosby, S. G.; Davidsson, Ö.; Emtenas, H.; Ertan, A.; Jurva, U.; Lemurell, M.; Gutierrez, P. M.; Nilsson, K.; O'Mahony, G.; Petersson, A. U.; Redzic, A.; Wägberg, F.; Yuan, Z.-Q. Identification and design of a novel series of MGAT2 inhibitors. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2721–2726. (c) Sercel, Z. P.; Sun, A. W.; Stoltz, B. M. Palladium-Catalyzed Decarboxylative Asymmetric Allylic Alkylation of 1,4-Diazepan-5-ones. *Org. Lett.* **2019**, *21*, 9158–9161.
- (7) (a) Hu, Y.; Phelan, V.; Ntai, I.; Farnet, C. M.; Zazopoulos, E.; Bachmann, B. O. Benzodiazepine biosynthesis in *Streptomyces refuineus*. *Chem. Biol.* **2007**, *14*, 691–701. (b) Mantaj, J.; Jackson, P. J. M.; Rahman, K. M.; Thurston, D. E. From Anthramycin to Pyrrolbenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). *Angew. Chem., Int. Ed.* **2017**, *56*, 462–488.
- (8) Fox, B. M.; Beck, H. P.; Roveto, P. M.; Kayser, F.; Cheng, Q.; Dou, H.; Williamson, T.; Treanor, J.; Liu, H.; Jin, L.; Xu, G.; Ma, J.; Wang, S.; Olson, S. H. A Selective Prostaglandin E2 Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated Clearance of Amyloid-Beta Plaques. *J. Med. Chem.* **2015**, *58*, 5256–5273.
- (9) Faisca Phillips, A. M. M.; Pombeiro, A. J. L. Modern Methods for the Synthesis of 1,4-Oxazepanes and their Benzo-Derivatives. In *Synthetic Approaches to Nonaromatic Nitrogen Heterocycles*; Wiley, 2020; pp 437–500.
- (10) Yang, J.; Che, X.; Dang, Q.; Wei, Z.; Gao, S.; Bai, X. Synthesis of tricyclic 4-chloropyrimido[4,5-b][1,4]benzodiazepines. *Org. Lett.* **2005**, *7*, 1541–1543.
- (11) (a) Loudni, L.; Roche, J.; Potiron, V.; Clarhaut, J.; Bachmann, C.; Gesson, J.-P.; Tranoy-Opalinski, I. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4819–4823. (b) Araujo, A. C.; Nicotra, F.; Airoidi, C.; Costa, B.; Giagnoni, G.; Fumagalli, P.; Cipolla, L. Synthesis and biological evaluation of novel rigid 1,4-benzodiazepine-2,5-dione chimeric scaffolds. *Eur. J. Org. Chem.* **2008**, 2008, 635–639.
- (12) De Silva, R. A.; Santra, S.; Andreana, P. R. A Tandem One-Pot, Microwave-Assisted Synthesis of Regiochemically Differentiated 1,2,4,5-Tetrahydro-1,4-benzodiazepin-3-ones. *Org. Lett.* **2008**, *10*, 4541–4544.
- (13) (a) Mohapatra, D. K.; Maity, P. K.; Shabab, M.; Khan, M. I. Click chemistry based rapid one-pot synthesis and evaluation for protease inhibition of new tetracyclic triazole fused benzodiazepine derivatives. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5241–5245. (b) Donald, J. R.; Martin, S. F. Synthesis and diversification of 1,2,3-triazole-fused 1,4-Benzodiazepine scaffolds. *Org. Lett.* **2011**, *13*, 852–855.
- (14) (a) Neukom, J. D.; Aquino, A. S.; Wolfe, J. P. Synthesis of Saturated 1,4-Benzodiazepines via Pd-Catalyzed Carboamination Reactions. *Org. Lett.* **2011**, *13*, 2196–2199. (b) Kundu, P.; Mondal, A.; Das, B.; Chowdhury, C. A Straightforward Approach for the Stereoselective Synthesis of (E)-2-Aryl/vinylmethylidene-1,4-benzodiazepines and -1,4-benzodiazepin-5-ones through Palladium/Charcoal-Catalyzed Reactions. *Adv. Synth. Catal.* **2015**, *357*, 3737–3752.
- (15) Sharma, U. K.; Sharma, N.; Vachhani, D. D.; Van der Eycken, E. V. Metal-mediated post-Ugi transformations for the construction of diverse heterocyclic scaffolds. *Chem. Soc. Rev.* **2015**, *44*, 1836–1860.
- (16) Liu, S.; Zhao, T.; Qu, J.; Wang, B. Expedient Synthesis of 1,4-Benzodiazepines via a Tandem Condensation/[1,5]-Hydride Transfer/Cyclization Process. *Adv. Synth. Catal.* **2018**, *360*, 4094–4098.
- (17) For asymmetric metal-catalyzed allyl C–H functionalizations, see: (a) Wang, P.-S.; Liu, P.; Zhai, Y.-J.; Lin, H.-C.; Han, Z.-Y.; Gong, L.-Z. Asymmetric Allylic C–H Oxidation for the Synthesis of Chromans. *J. Am. Chem. Soc.* **2015**, *137*, 12732–12735. (b) Ammann, S. E.; Liu, W.; White, M. C. Enantioselective Allylic C–H Oxidation of Terminal Olefins to Isochromans by Palladium(II)/Chiral Sulfoxide Catalysis. *Angew. Chem., Int. Ed.* **2016**, *55*, 9571–9575. (c) Chen, S.-S.; Wu, M.-S.; Han, Z.-Y. Palladium-Catalyzed Cascade sp² C–H Functionalization/Intramolecular Asymmetric Allylation: From Aryl Ureas and 1,3-Dienes to Chiral Indolines. *Angew. Chem., Int. Ed.* **2017**, *56*, 6641–6645.
- (18) (a) Meguro, M.; Yamamoto, Y. A new method for the synthesis of nitrogen heterocycles via palladium catalyzed intramolecular hydroamination of allenes. *Tetrahedron Lett.* **1998**, *39*, 5421–5424. (b) Lutete, L. M.; Kadota, I.; Yamamoto, Y. Palladium-Catalyzed

Intramolecular Asymmetric Hydroamination of Alkynes. *J. Am. Chem. Soc.* **2004**, *126*, 1622–1623.

(19) (a) Zhang, Z.; Liu, C.; Kinder, R. E.; Han, X.; Qian, H.; Widenhoefer, R. A. Highly Active Au(I) Catalyst for the Intramolecular exo-Hydrofunctionalization of Allenes with Carbon, Nitrogen, and Oxygen Nucleophiles. *J. Am. Chem. Soc.* **2006**, *128*, 9066–9073. (b) LaLonde, R. L.; Sherry, B. D.; Kang, E. J.; Toste, F. D. Gold(I)-Catalyzed Enantioselective Intramolecular Hydroamination of Allenes. *J. Am. Chem. Soc.* **2007**, *129*, 2452–2453. (c) Zhang, Z.; Bender, C. F.; Widenhoefer, R. A. Gold(I)-Catalyzed Dynamic Kinetic Enantioselective Intramolecular Hydroamination of Allenes. *J. Am. Chem. Soc.* **2007**, *129*, 14148–14149. (d) Lin, J.-S.; Li, T.-T.; Jiao, G.-Y.; Gu, Q.-S.; Cheng, J.-T.; Lv, L.; Liu, X.-Y. Chiral Bronsted Acid Catalyzed Dynamic Kinetic Asymmetric Hydroamination of Racemic Allenes and Asymmetric Hydroamination of Dienes. *Angew. Chem., Int. Ed.* **2019**, *58*, 7092–7096.

(20) (a) Liu, Z.; Breit, B. Rhodium-Catalyzed Enantioselective Intermolecular Hydroalkoxylation of Allenes and Alkynes with Alcohols: Synthesis of Branched Allylic Ethers. *Angew. Chem., Int. Ed.* **2016**, *55*, 8440–8443. (b) Spreider, P. A.; Haydl, A. M.; Heinrich, M.; Breit, B. Rhodium-Catalyzed Diastereoselective Cyclization of Allenyl-Sulfonylcarbamates: A Stereodivergent Approach to 1,3-Aminoalcohol Derivatives. *Angew. Chem., Int. Ed.* **2016**, *55*, 15569–15573. (c) Thieme, N.; Breit, B. Enantioselective and Regio-divergent Addition of Purines to Terminal Allenes: Synthesis of Abacavir. *Angew. Chem., Int. Ed.* **2017**, *56*, 1520–1524. (d) Zhou, Y.; Breit, B. Rhodium-Catalyzed Asymmetric N-H Functionalization of Quinazolinones with Allenes and Allylic Carbonates: The First Enantioselective Formal Total Synthesis of (–)-Chaetominine. *Chem. - Eur. J.* **2017**, *23*, 18156–18160. (e) Berthold, D.; Geissler, A. G. A.; Giofre, S.; Breit, B. Rhodium-Catalyzed Asymmetric Intramolecular Hydroamination of Allenes. *Angew. Chem., Int. Ed.* **2019**, *58*, 9994–9997. (f) Schmidt, J. P.; Breit, B. Transition metal catalyzed stereodivergent synthesis of syn- and anti- δ -vinyl-lactams: formal total synthesis of (–)-cermizine C and (–)-senepodine G. *Chem. Sci.* **2019**, *10*, 3074–3079. (g) Schmidt, J. P.; Breit, B. Rhodium-Catalyzed Cyclization of Terminal and Internal Allenols: An Atom Economic and Highly Stereoselective Access Towards Tetrahydropyrans. *Angew. Chem., Int. Ed.* **2020**, *59*, 23485–23490.

(21) (a) Only one example of 1,5-benzoxazepine has been reported. See ref 20e. For metal-catalyzed [5+2] heteroannulations to benzazepines, see: (b) He, H.; Liu, W.-B.; Dai, L.-X.; You, S.-L. Enantioselective Synthesis of 2,3-Dihydro-1H-benzo[b]azepines: Iridium-Catalyzed Tandem Allylic Vinylation/Amination Reaction. *Angew. Chem., Int. Ed.* **2010**, *49*, 1496–1499. (c) Rodríguez, A.; Albert, J.; Ariza, X.; Garcia, J.; Granell, J.; Farràs, J.; La Mela, A.; Nicolás, E. Catalytic C–H Activation of Phenylethylamines or Benzylamines and Their Annulation with Allenes. *J. Org. Chem.* **2014**, *79*, 9578–9585. (d) Bai, L.; Wang, Y.; Ge, Y.; Liu, J.; Luan, X. Diastereoselective Synthesis of Dibenzo[b,d]azepines by Pd(II)-Catalyzed [5 + 2] Annulation of o-Arylanilines with Dienes. *Org. Lett.* **2017**, *19*, 1734–1737. (e) Cendón, B.; Casanova, N.; Comanescu, C.; García-Fandiño, R.; Seoane, A.; Gúliás, M.; Mascareñas, J. L. Palladium-Catalyzed Formal (5 + 2) Annulation between ortho-Alkenylanilides and Allenes. *Org. Lett.* **2017**, *19*, 1674–1677. (f) Wu, L.; Meng, Y.; Ferguson, J.; Wang, L.; Zeng, F. Palladium-Catalyzed Oxidative Annulation of ortho-Alkenylanilines and Allenes: An Access to Benzo[b]azepines. *J. Org. Chem.* **2017**, *82*, 4121–4128. (g) Velasco-Rubio, A.; Varela, J. A.; Saá, C. Palladium-Catalyzed [5 + 2] Heteroannulation of Phenethylamides with 1,3-Dienes to Dopaminergic 3-Benzazepines. *Org. Lett.* **2020**, *22*, 3591–3595.

(22) PMP-protected anilines (anisidines) have been used as excellent nucleophiles in Pd-catalyzed hydroaminations of dienes and are easily removed by oxidation. Löber, O.; Kawatsura, M.; Hartwig, J. F. Palladium-Catalyzed Hydroamination of 1,3-Dienes: A Colorimetric Assay and Enantioselective Additions. *J. Am. Chem. Soc.* **2001**, *123*, 4366–4367.

(23) (a) The six-membered 3-propenyl isoquinoline **2c'** was also isolated in a low 20% yield as a mixture of *Z* and *E* isomers. See Supporting Information and ref 20e. For an enantioselective Ru-catalyzed heterocyclization through a NTs nucleophile to an allylic alcohol giving an α -vinyl-2-benzazepine, see: (b) Seki, T.; Tanaka, S.; Kitamura, M. Enantioselective Synthesis of Pyrrolidine-, Piperidine-, and Azepane-Type N-Heterocycles with α -Alkenyl Substitution: The CpRu-Catalyzed Dehydrative Intramolecular N-Allylation Approach. *Org. Lett.* **2012**, *14*, 608–611.

(24) For other chiral ligands and conditions used, see Supporting Information.

(25) CCDC 1983304 contains the supplementary crystallographic data for compound **2e**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

(26) With *rac*-BNP acid as a Brønsted acid, low chemical yields of **2e** were obtained.

(27) Nor 1,1-disubstituted allenols neither trisubstituted allenols cyclized under standard conditions. See Supporting Information for details.

(28) (a) Hartwig, J. F.; Stanley, L. M. Mechanistically Driven Development of Iridium Catalysts for Asymmetric Allylic Substitution. *Acc. Chem. Res.* **2010**, *43*, 1461–1475. (b) Trost, B. M.; Zhang, T.; Sieber, J. D. Catalytic asymmetric allylic alkylation employing heteroatom nucleophiles: a powerful method for C–X bond formation. *Chem. Sci.* **2010**, *1*, 427–440. (c) Chen, Q.-A.; Chen, Z.; Dong, V. M. Rhodium-Catalyzed Enantioselective Hydroamination of Alkynes with Indolines. *J. Am. Chem. Soc.* **2015**, *137*, 8392–8395. (d) Huang, L.; Arndt, M.; Gooßen, K.; Heydt, H.; Gooßen, L. J. Late Transition Metal-Catalyzed Hydroamination and Hydroamidation. *Chem. Rev.* **2015**, *115*, 2596–2697. (e) Yang, X.-H.; Dong, V. M. Rhodium-catalyzed hydrofunctionalization: Enantioselective coupling of indolines and 1,3-dienes. *J. Am. Chem. Soc.* **2017**, *139*, 1774–1777.

(29) From the X-ray structure of **2e**, a tentative interpretation would be that “outer” sphere pathway is perhaps more favored due to the tendency to establish attractive π – π interactions between both aryl rings on nitrogens of **3d–k**.

(30) Ammann, S. E.; Rice, G. T.; White, M. C. Terminal Olefins to Chromans, Isochromans, and Pyrans via Allylic C–H Oxidation. *J. Am. Chem. Soc.* **2014**, *136*, 10834–10837.

(31) Velasco-Rubio, A.; Alexy, E. J.; Yoritake, M.; Wright, A. C.; Stoltz, B. M. Stereospecific Overman Rearrangement of Substituted Cyclic Vinyl Bromides: Access to Fully Substituted α -Amino Ketones. *Org. Lett.* **2019**, *21*, 8962–8965.

(32) Barraza, S. J.; Denmark, S. E. Synthesis, Reactivity, Functionalization, and ADMET Properties of Silicon-Containing Nitrogen Heterocycles. *J. Am. Chem. Soc.* **2018**, *140*, 6668–6684.

(33) Molinari, A. J.; Trybulski, E. J.; Bagli, J.; Croce, S.; Considine, J.; Qi, J.; Ali, K.; DeMaio, W.; Lihotz, L.; Cochran, D. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5796–5800.

(34) Bernárdez, R.; Suárez, J.; Fañanás-Mastral, M.; Varela, J. A.; Saá, C. Tandem Long Distance Chain-Walking/Cyclization via RuH₂(CO)(PPh₃)₃/Brønsted Acid Catalysis: Entry to Aromatic Oxazaheterocycles. *Org. Lett.* **2016**, *18*, 642–645.

(35) Nolla-Saltiel, R.; Robles-Marín, E.; Porcel, S. Silver(I) and gold(I)-promoted synthesis of alkylidene lactones and 2H-chromenes from salicylic and anthranilic acid derivatives. *Tetrahedron Lett.* **2014**, *55*, 4484–4488.

(36) Oonishi, Y.; Saito, A.; Sato, Y. Rhodium(I)-Catalyzed Intermolecular [2 + 2+2] Cycloaddition of Allenyl Aldehydes with Alkynes and Related Cyclization. *Asian J. Org. Chem.* **2015**, *4*, 81–86.

(37) Mukherjee, A.; Liu, R.-S. Chemoselectivities in the Platinum-Catalyzed Hydrative Carbocyclizations of Oxo-Alkyne-Nitrile Functionalities. *Org. Lett.* **2011**, *13*, 660–663.

(38) de Orbe, M. E.; Zanini, M.; Quinonero, O.; Echavarren, A. M. Gold- or Iridium-Catalyzed Cross-Coupling of Bromoalkynes with

Allylsilanes through a Concealed Rearrangement. *ACS Catal.* **2019**, *9*, 7817–7822.

(39) Zhao, C.-Y.; Li, K.; Pang, Y.; Li, J.-Q.; Liang, C.; Su, G.-F.; Mo, D.-L. Iodine(III) Reagent-Mediated Intramolecular Amination of 2-Alkenylanilines to Prepare Indoles. *Adv. Synth. Catal.* **2018**, *360*, 1919–1925.

(40) Yang, F.; Ding, D.; Wang, C. Nickel-Catalyzed Directed Cross-Electrophile Coupling of Phenolic Esters with Alkyl Bromides. *Org. Lett.* **2020**, *22*, 9203–9209.

(41) Theeraladanon, C.; Arisawa, M.; Nishida, A.; Nakagawa, M. A novel synthesis of substituted quinolines using ring-closing metathesis (RCM): its application to the synthesis of key intermediates for anti-malarial agents. *Tetrahedron* **2004**, *60*, 3017–3035.

(42) Nishiguchi, A.; Ikemoto, T.; Ito, T.; Miura, S.; Tomimatsu, K. Preparation of a 1-unsubstituted 2,3-dihydro-1-benzazepine derivative. *Heterocycles* **2007**, *71*, 1183–1192.

(43) Iioka, R.; Yorozu, K.; Sakai, Y.; Kawai, R.; Hatae, N.; Takashima, K.; Tanabe, G.; Wasada, H.; Yoshimatsu, M. Synthesis of Azepino[1,2-a]indole-10-amines via [6 + 1] Annulation of Ynenitriles with Reformatsky Reagent. *Eur. J. Org. Chem.* **2021**, *2021*, 1553–1558.

(44) (a) Jia, M.-Q.; You, S.-L. N-Heterocyclic Carbene-Catalyzed Enantioselective Intramolecular N-Tethered Aldehyde–Ketone Benzoin Reactions. *ACS Catal.* **2013**, *3*, 622–624. (b) Guo, Z.; Jia, H.; Liu, H.; Wang, Q.; Huang, J.; Guo, H. A [4 + 3] Annulation Reaction of aza-o-Quinone Methides with Arylcarbohydrazonoyl Chlorides for Synthesis of 2,3-Dihydro-1H-benzo[e][1,2,4]triazepines. *Org. Lett.* **2018**, *20*, 2939–2943.

(45) Ascic, E.; Jensen, J. F.; Nielsen, T. E. Synthesis of Heterocycles through a Ruthenium-Catalyzed Tandem Ring-Closing Metathesis/Isomerization/N-Acyliminium Cyclization Sequence. *Angew. Chem., Int. Ed.* **2011**, *50*, 5188–5191.